

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/12, C07K 14/71, C12N 15/85, 5/10, A61K 38/17, 48/00, 39/395, G01N 33/68	A1	(11) International Publication Number: WO 00/20579 (43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/CA99/00912 (22) International Filing Date: 1 October 1999 (01.10.99) (30) Priority Data: 09/165,192 2 October 1998 (02.10.98) US (71) Applicant (for all designated States except US): McMASTER UNIVERSITY [CA/CA]; Health Science Centre, Room 3N43, 1200 Main Street, Hamilton, Ontario L8N 3Z5 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): MULLER, William, J. [CA/CA]; #65 7 Davidson Boulevard, Dundas, Ontario L9H 6Y7 (CA). SIEGEL, Peter, M. [CA/CA]; Apartment 607, 200 Main Street West, Hamilton, Ontario L8S 4M8 (CA). (74) Agent: BERESKIN & PARR; 40th floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: SPLICED FORM OF *ERBB-2*/NEU ONCOGENE**(57) Abstract**

A novel spliced form of *erbB-2* oncogene that encodes a constitutively tyrosine phosphorylated *erbB-2* receptor is described. The protein has an in frame deletion of 16 amino acids, two of which are conserved cysteine residues. The protein may be useful in developing remedies to control cell transformation such as in breast cancer.

A**B**

WT (Human *erbB-2*)

ACCCACTCTGTGTGGACCTGGATGACAAGGGCTGACCGGCGAGAGAGGACGACCTGTGACGTGC
 T H S C V D L D D K G C P A E Q R A S P L T S

Alternate splice (Human *erbB-2*)

ACCCACTG
 T H S

CCTCTGACCTGC
 P L T S

C

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Title: Spliced Form of *ErbB-2/Neu* Oncogene

FIELD OF THE INVENTION

5 The invention relates to a novel spliced form of gene that encodes a constitutively tyrosine phosphorylated *erbB-2* receptor. The invention includes nucleic acid molecules encoding the protein and truncations, analogs, and homologs of the protein; and uses of the protein and nucleic acid molecules in controlling cell transformation and cancer.

BACKGROUND OF THE INVENTION

10 Activation of growth factor receptor tyrosine kinases has been implicated in the malignant progression of a number of different tumor types. For example, elevated expression of the *erbB-2* oncogene has been observed in a significant proportion of human breast and ovarian cancers (Slamon et al., 1987; 1989). Moreover, the extent of overexpression of *erbB-2* in lymph node positive breast cancer patients has been inversely correlated with patient survival (reviewed in Hynes and Stern, 1994). Direct evidence for the importance of this gene
15 in the induction of mammary tumors has been obtained from studies of transgenic mice that express either an activated or wild-type neu cDNA in the mammary epithelium. Mammary epithelial expression of the activated version of neu results in the rapid induction of multifocal mammary tumors in every female transgenic animal (Muller et al., 1988; Guy et al., 1996). In contrast, mammary epithelial expression of the neu proto-oncogene leads to
20 development of focal mammary tumors which develop after a longer latency period (Guy et al., 1992). Consistent with clinical observations indicating a negative correlation of *erbB-2* amplification with patient survival, these wild-type neu transgenic strains frequently developed secondary metastatic lesions in the lung (Guy et al., 1992).

Biochemical and genetic analyses of tumor progression in these transgenic strains has
25 revealed that tumor progression in transgenic mice expressing the neu proto-oncogene in the mammary epithelium frequently involves the acquisition of activating mutations in the neu transgene (Siegel et al., 1994). Sequence analyses of these somatic mutations revealed that these alterations map to a cysteine rich region in Neu that is highly conserved among members of the epidermal growth factor receptor family. Indeed, it has been demonstrated
30 that these alterations result in the oncogenic activation of Neu (Siegel et al., 1994; Siegel and Muller, 1996). Significantly, these sequence alterations appear to affect the balance of cysteines within this region through the deletion or insertion of a cysteine residue. It has been further demonstrated that these alterations in Neu lead to receptor dimerization and activation through the formation of intermolecular cysteine disulfide bonds (Siegel and
35 Muller, 1996). Interestingly, oncogenic activation of these altered Neu molecules is dependent on the formation of intermolecular disulfide bonds since the addition of exogenous reducing agents can ablate the in vitro transforming potential of these activated neu alleles (Siegel and Muller, 1996).

Although these observations suggest that activation of the Neu receptor in this transgenic mouse model is an important step, the relevance to clinical human breast cancer is unclear.

SUMMARY OF THE INVENTION

5 The present inventors have identified a spliced form of mRNA which translates into an *erbB-2* receptor which has increased catalytic activity capable of transforming Rat-1 fibroblasts. The increased catalytic activity is reflected by increased tyrosine phosphorylation of the receptor. The increase in catalytic activity of this receptor may constitute a significant causative factor in the genesis of human breast tumors.

10 The present invention therefore provides a purified and isolated nucleic acid molecule (SPLICE) comprising a sequence encoding a constitutively tyrosine phosphorylated *erbB-2* receptor, which is the protein of the invention, having increased catalytic activity and capable of transforming Rat-1 fibroblasts and which may generally be referred to as SPLICE *erbB-2* protein.

15 In an embodiment of the invention, the purified and isolated nucleic acid molecule comprises: (i) a nucleic acid sequence encoding a SPLICE *erbB-2* protein having the amino acid sequence as shown in Figure 2 and SEQ ID NO:2; and, (ii) nucleic acid sequences complementary to (i).

20 In a preferred embodiment of the invention, the purified and isolated nucleic acid molecule comprises:

(i) a nucleic acid sequence encoding a SPLICE *erbB-2* protein having the nucleic acid sequence as shown in Figure 1 or SEQ ID NO:1, wherein T can also be U;

(ii) a nucleic acid sequence complementary to (i), preferably complementary to the full length nucleic acid sequence shown in Figure 1;

25 (iii) a nucleic acid molecule differing from any of the nucleic acids of (i) and (ii) in codon sequences due to the degeneracy of the genetic code.

30 The invention also contemplates an isolated and purified (a) nucleic acid molecule comprising a sequence encoding a truncation of SPLICE *erbB-2*, an analog, homolog or truncation thereof; (b) nucleic acid molecule comprising a sequence which hybridizes under high stringency conditions to the nucleic acid encoded by a SPLICE *erbB-2* protein having the amino acid sequence as shown in Figure 2 or SEQ ID NO:2, wherein T can also be U, or complementary sequences thereto, or by a related protein; and (c) nucleic acid molecule comprising a sequence which hybridizes under high stringency conditions to the nucleic acid sequence as shown in Figure 1, wherein T can also be U, or complementary sequences thereto.

35 The invention further contemplates a purified and isolated double stranded nucleic acid molecule containing a nucleic acid molecule of the invention, hydrogen bonded to a complementary nucleic acid base sequence.

The nucleic acid molecules of the invention may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Accordingly, recombinant expression vectors adapted for transformation of a host cell, preferably mammary cells, may be constructed
5 which comprise a nucleic acid molecule of the invention and one or more transcription and translation elements operatively linked to the nucleic acid molecule.

The recombinant expression vector can be used to prepare transformed host cells expressing a SPLICE *erbB-2* protein of the invention or a related protein. Therefore, the invention further provides host cells containing a recombinant molecule of the invention. The
10 invention also contemplates transgenic non-human mammals whose germ cells and somatic cells contain a recombinant molecule comprising a nucleic acid molecule of the invention which encodes a SPLICE *erbB-2* protein or an analog thereof, i.e., the protein with an insertion, substitution or deletion mutation.

The invention further provides a method for preparing a SPLICE protein, or a related
15 protein utilizing the purified and isolated nucleic acid molecules of the invention. In an embodiment a method for preparing a SPLICE *erbB-2* protein is provided comprising (a) transferring a recombinant expression vector of the invention into a host cell; (b) selecting transformed host cells from untransformed host cells; (c) culturing a selected transformed host cell under conditions which allow expression of the SPLICE *erbB-2* protein; and (d) isolating
20 the SPLICE *erbB-2* protein.

The invention further broadly contemplates a purified and isolated SPLICE *erbB-2* protein which is capable of transforming Rat-1 fibroblasts. The SPLICE *erbB-2* protein has an in frame deletion of sixteen (16) amino acids, two of which are conserved cysteine residues and an approximate molecular weight of 50KD. In an embodiment of the invention, a
25 purified SPLICE *erbB-2* protein is provided which has the amino acid sequence as shown in Figure 2 or SEQ ID NO:2. The invention also includes truncations of the protein and analogs, homologs, and isoforms of the protein and truncations thereof.

The SPLICE *erbB-2* proteins of the invention may be conjugated with other molecules, such as proteins to prepare fusion proteins. This may be accomplished, for example, by the
30 synthesis of N-terminal or C-terminal fusion proteins.

The invention further contemplates antibodies having specificity against an epitope of a SPLICE *erbB-2* protein of the invention. Antibodies may be labelled with a detectable substance and they may be used to detect the SPLICE *erbB-2* protein of the invention in tissues and cells.

35 The invention also permits the construction of nucleotide probes which are unique to the nucleic acid molecules of the invention and accordingly to a SPLICE *erbB-2* protein of the invention. Thus, the invention also relates to a probe comprising a sequence encoding a SPLICE *erbB-2* protein or fragment thereof. The probe may be labelled, for example, with a

detectable substance and it may be used to select from a mixture of nucleotide sequences a nucleotide sequence coding for a protein which displays one or more of the properties of the protein of the invention. The probes may also be used to detect a nucleic acid encoding a SPLICE *erbB-2* protein of the invention in tissues and cells. In particular, the probes may be used as a diagnostic tool on biopsied tissues to assess the transformed state of the cell.

5 The SPLICE *erbB-2* protein is likely involved in the induction of human breast tumors. Accordingly, in one embodiment the present invention provides a method of modulating SPLICE *erbB-2* activity comprising administering an effective amount of inhibitor of SPLICE *erbB-2* protein activity to a cell or animal in need thereof. In such an embodiment, it may be desirable to inhibit the expression of the SPLICE *erbB-2* protein. Accordingly, the present invention provides a method of inhibiting or reducing cell transformation comprising administering an agent that inhibits the expression or activity of the SPLICE *erbB-2* protein to an animal or cell in need thereof. Agents that may inhibit the SPLICE *erbB-2* protein include antibodies to the protein or antisense oligonucleotides complimentary to a portion of a nucleic acid sequence encoding the protein.

15 The invention still further provides a method for identifying a substance which is capable of binding to a SPLICE *erbB-2* protein or inactive form thereof, comprising reacting the SPLICE *erbB-2* protein, or inactivated form, with at least one substance which potentially can bind with the SPLICE *erbB-2* protein or an inactivated form thereof, under conditions which permit the formation of complexes between the substance and the protein or an inactivated form thereof, and assaying for complexes, for free substance, for non-complexed SPLICE *erbB-2* protein or for activation of SPLICE *erbB-2*. Specifically, a yeast two hybrid assay system may be utilized as a method for identifying proteins which interact with the protein (Fields, S. and Song, O. 1989, Nature, 34:245-247).

20 Still further, the invention provides a method for assaying a medium for the presence of an agonist or antagonist of the interaction of a SPLICE *erbB-2* protein or an activated form thereof, and a substance which binds to the protein or an activated form thereof. In one embodiment, the method comprises providing a known concentration of a SPLICE *erbB-2* protein, with a substance which is capable of binding to the protein and a suspected agonist or antagonist substance under conditions which permit the formation of complexes between the substance and SPLICE *erbB-2* protein, and assaying for complexes, free substance, non-complexed SPLICE *erbB-2* protein, or for activation of the protein.

25 Substances which affect the SPLICE *erbB-2* protein may also be identified using the methods of the invention by comparing the pattern and level of expression of the protein in tissues and cells in the presence, and in the absence of the substance.

35 Antibodies to SPLICE *erbB-2* protein or antisense oligonucleotides complimentary to a nucleic acid encoding the SPLICE *erbB-2* protein as well as substances identified using a method of the invention may be used in the treatment of conditions involving cell

transformation such as cancer. Accordingly, the substances may be formulated into pharmaceutical compositions for administration to individuals suffering from cancer and preferably breast cancer. Accordingly, the substances may be formulated into pharmaceutical compositions for administration to individuals suffering from cancer.

- 5 Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art
10 from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the cDNA sequence of the SPLICE *erbB-2* protein of the invention.

Figure 2 shows the amino acid sequence of SPLICE *erbB-2* protein.

- Figure 3a provides a schematic representation of a small region of the human *erbB-2*
15 genomic locus indicating the exon-intron boundaries.

Figure 3b shows an alignment of the wild-type and alternatively spliced *erbB-2* messages indicating the sequences removed by the aberrant splicing event (grey box).

Figure 3c shows alternate mRNA splicing results in an *erbB-2* transcript harboring an in-frame deletion.

- 20 Figure 4a shows partial amino acid sequence alignment of the wild-type and altered *erbB-2* receptors tested in Rat-1 focus assays.

Figure 4b shows representative plates from focus assay #1 (see Table 1) illustrating the relative transforming abilities of the various forms of *erbB-2* indicated in Figure 4a.

- Figure 5a shows immunoblots of lysates from stable cell lines expressing wild-type
25 *ErbB-2* (WT) or the three altered receptors (VE, ECD, SPLICE).

Figure 5b shows immunoblots of lysates from stable cell lines expressing the various *ErbB-2* receptors.

DETAILED DESCRIPTION OF THE INVENTION

- The following standard abbreviations for amino acid residues are used throughout
30 the specification: A, Ala - alanine; C, Cys - cysteine; D, Asp- aspartic acid; E, Glu - glutamic acid; F, Phe - phenylalanine; G, Gly - glycine; H, His - histidine; I, Ile - isoleucine; K, Lys - lysine; L, Leu - leucine; M, Met - methionine; N, Asn - asparagine; P, Pro - proline; Q, Gln - glutamine; R, Arg - arginine; S, Ser - serine; T, Thr - threonine; V, Val - valine; W, Trp - tryptophan; Y, Tyr - tyrosine; and p.Y., P.Tyr - phosphotyrosine.

1. Nucleic Acid Molecules Encoding SPLICE *erbB-2*

a. The Nucleic Acid Molecules

As mentioned above, the invention provides an isolated and purified nucleic acid molecule having a sequence encoding a SPLICE *erbB-2* protein. The term "isolated and

purified" refers to a nucleic acid substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors, or other chemicals when chemically synthesized. The term "nucleic acid" is intended to include DNA and RNA and can be either double stranded or single stranded.

5 The nucleic acid sequence of the cDNA encoding the SPLICE *erbB-2* protein is shown in Figure 1 and SEQ.ID.NO.:1.

It will be appreciated that the invention includes nucleic acid molecules encoding truncations of SPLICE *erbB-2* protein, and analogs and homologs of the protein and truncations thereof, as described herein. It will further be appreciated that variant forms of
10 nucleic acid molecules of the invention which arise by alternative splicing of an mRNA corresponding to a cDNA of the invention are encompassed by the invention.

Another aspect of the invention provides a nucleic acid molecule which hybridizes under high stringency conditions to a nucleic acid molecule which comprises a sequence which encodes SPLICE *erbB-2* protein having the amino acid sequence shown in Figure 2.
15 Appropriate stringency conditions which promote DNA hybridization are known to those skilled in the art, or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C may be employed. The stringency may be selected based on the conditions used in the wash step. By way of example, the salt
20 concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

Isolated and purified nucleic acid molecules encoding a protein having the activity of SPLICE *erbB-2* protein as described herein, and having a sequence which differs from the
25 nucleic acid sequence shown in Figure 1, due to degeneracy in the genetic code are also within the scope of the invention.

In addition, DNA sequence polymorphisms within the nucleotide sequence of SPLICE *erbB-2* protein (especially those within the third base of a codon) may result in "silent" mutations in the DNA which do not affect the amino acid encoded. However, DNA sequence
30 polymorphisms may lead to changes in the amino acid sequences of the protein within a population. It will be appreciated by one skilled in the art that these variations in one or more nucleotides of the nucleic acids encoding proteins having the activity of the SPLICE *erbB-2* protein may exist among individuals within a population due to natural allelic variation. Any and all such nucleotide variations and resulting amino acid polymorphisms
35 are within the scope of the invention.

b. Isolation of Purified Nucleic Acid Molecules

An isolated and purified nucleic acid molecule of the invention which comprises DNA can be isolated by preparing a labelled nucleic acid probe based on all or part of the

nucleic acid sequence shown in Figure 1 and using this labelled nucleic acid probe to screen an appropriate DNA library (e.g. a cDNA or genomic DNA library). For instance, a cDNA library made from lymphocytes such as B cells can be used to isolate a cDNA encoding a protein having SPLICE *erbB-2* activity by screening the library with the labelled probe using standard techniques. Alternatively, a genomic DNA library can be similarly screened to isolate a genomic clone encompassing a gene encoding a SPLICE *erbB-2* protein. Nucleic acids isolated by screening of a cDNA or genomic DNA library can be sequenced by standard techniques.

An isolated and purified nucleic acid molecule of the invention which is DNA can also be isolated by selectively amplifying a nucleic acid encoding a SPLICE *erbB-2* protein using the polymerase chain reaction (PCR) methods and cDNA or genomic DNA. It is possible to design synthetic oligonucleotide primers from the nucleotide sequence shown in Figure 1. A nucleic acid can be amplified from cDNA or genomic DNA using these oligonucleotide primers and standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. It will be appreciated that cDNA may be prepared from mRNA, by isolating total cellular mRNA by a variety of techniques, for example, by using the guanidinium-thiocyanate extraction procedure of Chirgwin et al., *Biochemistry*, 18, 5294-5299 (1979). cDNA is then synthesized from the mRNA using reverse transcriptase (for example, Moloney MLV reverse transcriptase available from Gibco/BRL, Bethesda, MD, or AMV reverse transcriptase available from Seikagaku America, Inc., St. Petersburg, FL).

An isolated and purified nucleic acid molecule of the invention which is RNA can be isolated by cloning a cDNA encoding a SPLICE *erbB-2* protein into an appropriate vector which allows for transcription of the cDNA to produce an RNA molecule which encodes a protein which exhibits SPLICE *erbB-2* protein activity. For example, a cDNA can be cloned downstream of a bacteriophage promoter, (e.g. a T7 promoter) in a vector, cDNA can be transcribed *in vitro* with T7 polymerase, and the resultant RNA can be isolated by standard techniques.

c. Chemical Synthesis of Nucleic Acid Molecules

A nucleic acid molecule of the invention may also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See e.g., Itakura et al. U.S. Patent No. 4,598,049; Caruthers et al. U.S. Patent No. 4,458,066; and Itakura U.S. Patent Nos. 4,401,796 and 4,373,071).

Determination of whether a particular nucleic acid molecule encodes a protein having SPLICE *erbB-2* protein activity can be accomplished by expressing the cDNA in an appropriate host cell by standard techniques, and testing the ability of the expressed protein

to transform Rat-1 fibroblasts. A cDNA having the biological activity of a SPLICE *erbB-2* protein so isolated can be sequenced by standard techniques, such as dideoxynucleotide chain termination or Maxam-Gilbert chemical sequencing, to determine the nucleic acid sequence and the predicted amino acid sequence of the encoded protein.

5 *d. Antisense Nucleic Acid Molecules*

The sequence of a nucleic acid molecule of the invention may be inverted relative to its normal presentation for transcription to produce an antisense nucleic acid molecule. An antisense nucleic acid molecule may be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.

10 II. SPLICE *erbB-2* Proteins

As mentioned above, the present invention relates to an isolated SPLICE *erbB-2* protein having an in frame deletion of sixteen (16) amino acids, two of which are conserved cysteine residues. The amino acid sequence of a SPLICE *erbB-2* protein, Seq I.D. No. 2, of the present invention is shown in Figure 2.

15 The inventors have demonstrated that SPLICE *erbB-2* protein is expressed in human breast tissue; in low levels in normal tissue and high levels in tumor tissue. The inventors have also demonstrated that the SPLICE *erbB-2* protein is constitutively tyrosine phosphorylated, and that this protein is capable of transforming Rat-1 fibroblasts.

20 The proteins of the present invention include truncations of the SPLICE *erbB-2* protein, and analogs, and homologs and truncations thereof as described herein.

Truncated proteins may have an amino group (-NH₂), a hydrophobic group (for example, carbobenzoxy, dansyl, or T-butyloxycarbonyl), an acetyl group, a 9-fluorenylmethoxy-carbonyl (PMOC) group, or a macromolecule including but not limited to lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates at the amino terminal
25 end. The truncated proteins may have a carboxyl group, an amino group, a T-butyloxycarbonyl group, or a macromolecule including but not limited to lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates at the carboxy terminal end.

Proteins of the invention may also include analogs of the SPLICE *erbB-2* protein as shown in Figure 2 or truncations thereof as described herein, which may include, but are not
30 limited to one or more amino acid substitutions, insertions, and/or deletions. Amino acid substitutions may be of a conserved or non-conserved nature. Conserved amino acid substitutions involve replacing one or more amino acids of the SPLICE *erbB-2* amino acid sequence with amino acids of similar charge, size, and/or hydrophobicity characteristics. When only conserved substitutions are made the resulting analog should be functionally
35 equivalent to the SPLICE *erbB-2* protein. Non-conserved substitutions involve replacing one or more amino acids of the SPLICE *erbB-2* amino acid sequence with one or more amino acids which possess dissimilar charge, size, and/or hydrophobicity characteristics.

One or more amino acid insertions may be introduced into the SPLICE *erbB-2* protein. Amino acid insertions may consist of single amino acid residues or sequential amino acids ranging from 2 to 15 amino acids in length.

5 The proteins of the invention also include homologs of the SPLICE *erbB-2* protein (Figure 2) and/or truncations thereof as described herein. Such homologs are proteins whose amino acid sequences are comprised of the amino acid sequences of SPLICE *erbB-2* protein regions from other species that hybridize under stringent hybridization conditions with a probe used to obtain the protein.

10 The invention also contemplates isoforms of the protein of the invention. An isoform contains the same number and kinds of amino acids as the protein of the invention or subtle spliced differences which alter the overall number of amino acids resulting in a slight shift in molecular weight. The isoforms contemplated by the present invention are those having the same properties as a SPLICE *erbB-2* protein of the invention as described herein.

15 The present invention also includes SPLICE *erbB-2* protein conjugated with a selected protein, or a selectable marker protein (see below) to produce fusion proteins. Further, the present invention also includes activated or phosphorylated SPLICE *erbB-2* proteins of the invention. Additionally, immunogenic portions of SPLICE *erbB-2* proteins are within the scope of the invention.

20 Proteins of the invention may be prepared using recombinant DNA methods. Accordingly, the nucleic acid molecules of the present invention having a sequence which encodes a SPLICE *erbB-2* protein of the invention may be incorporated in a known manner into an appropriate expression vector which ensures good expression of the protein. Possible expression vectors include but are not limited to cosmids, plasmids, or modified viruses (e.g. replication defective retroviruses, adenoviruses and adeno-associated viruses), so long as the
25 vector is compatible with the host cell used. The expression vectors are "suitable for transformation of a host cell", means that the expression vectors contain a nucleic acid molecule of the invention and regulatory sequences selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid molecule. Operatively linked is intended to mean that the nucleic acid is linked to regulatory sequences in a manner
30 which allows expression of the nucleic acid.

The invention therefore contemplates a recombinant expression vector of the invention containing a nucleic acid molecule of the invention, or a fragment thereof, and the necessary regulatory sequences for the transcription and translation of the inserted protein-sequence. Suitable regulatory sequences may be derived from a variety of sources,
35 including mammalian, bacterial, fungal, viral or insect genes (For example, see the regulatory sequences described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Selection of appropriate regulatory sequences is dependent on the host cell chosen as discussed below, and may be readily

accomplished by one of ordinary skill in the art. Examples of such regulatory sequences include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a ribosomal binding sequence, including a translation initiation signal. Additionally, depending on the host cell chosen and the vector employed, other sequences, such as an origin of replication, additional DNA restriction sites, enhancers, and sequences conferring inducibility of transcription may be incorporated into the expression vector. It will also be appreciated that the necessary regulatory sequences may be supplied by the native the SPLICE *erbB-2* gene and/or its flanking regions.

The invention further provides a recombinant expression vector comprising a DNA nucleic acid molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression, by transcription of the DNA molecule, of an RNA molecule which is antisense to the nucleotide sequence of SEQ ID NO: 1. Regulatory sequences operatively linked to the antisense nucleic acid can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance a viral promoter and/or enhancer, or regulatory sequences can be chosen which direct tissue or cell type specific expression of antisense RNA. Antisense oligodeoxynucleotides seem promising for the purposes of inhibiting expression of genes as long as they are efficiently protected against degradation and targetted into cells. Supramolecular biovectors (SMBV) are antisense oligonucleotide carriers which improve both cellular uptake and protection of oligodeoxynucleotide (see for example Allal, C. et al. Br. J. Cancer 77:1448-1453 (1998)) and are further provided as part of the present invention.

The recombinant expression vectors of the invention may also contain a selectable marker gene which facilitates the selection of host cells transformed or transfected with a recombinant molecule of the invention. Examples of selectable marker genes are genes encoding a protein such as G418 and hygromycin which confer resistance to certain drugs, β -galactosidase, chloramphenicol acetyltransferase, firefly luciferase, green fluorescent protein, alkaline phosphatase, yellow fluorescent protein, blue fluorescent protein or an immunoglobulin or portion thereof such as the Fc portion of an immunoglobulin preferably IgG. Transcription of the selectable marker gene is monitored by changes in the concentration of the selectable marker protein such as β -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. If the selectable marker gene encodes a protein conferring antibiotic resistance such as neomycin resistance, transformant cells can be selected with G418. Cells that have incorporated the selectable marker gene will survive, while the other cells die. This makes it possible to visualize and assay for expression of recombinant expression vectors of the invention and in particular to determine the effect of a mutation on expression and phenotype. It will be appreciated that selectable markers can be introduced on a separate vector from the nucleic acid of interest.

The recombinant expression vectors may also contain genes which encode a fusion moiety which provides increased expression of the recombinant protein; increased solubility of the recombinant protein; and aid in the purification of the target recombinant protein by acting as a ligand in affinity purification. For example, a proteolytic cleavage site may be added to the target recombinant protein to allow separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the recombinant protein.

Recombinant expression vectors can be introduced into host cells to produce a transformant host cell. The term "transformant host cell" is intended to include prokaryotic and eukaryotic cells which have been transformed or transfected with a recombinant expression vector of the invention. The terms "transformed with", "transfected with", "transformation" and "transfection" are intended to encompass introduction of nucleic acid (e.g. a vector) into a cell by one of many possible techniques known in the art. Prokaryotic cells can be transformed with nucleic acid by, for example, electroporation or calcium-chloride mediated transformation. Nucleic acid can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofectin, electroporation or microinjection. Suitable methods for transforming and transfecting host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.

Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells. For example, the PKT proteins of the invention may be expressed in mammalian cells, bacterial cells such as *E. coli*, insect cells (using baculovirus) or yeast cells. Other suitable host cells can be found in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1991).

Mammalian cells suitable for carrying out the present invention include, among others: Cos-7 (green monkey kidney), Saqs-2 (human osteosarcoma), PC12, NIH-3T3, MONC, SY5Y, P19, G361 (human melanoma), A549 (human lung carcinoma), SW480 (human colorectal adenocarcinoma), Raji (human Burkitt's lymphoma), MOLT-4 (human lymphoblastic leukemia), K562 (human chronic myelogenous leukemia), S3 (Hela cells), HL-60 (human promyelocytic leukemia, and breast cancer cell lines; T47Ds, MCF-7s and C127s, COS (e.g., ATCC No. CRL 1650 or 1651), BHK (e.g., ATCC No. CRL 6281), CHO (ATCC No. CCL 61), HeLa (e.g., ATCC No. CCL 2), 293 (ATCC No. 1573) and NS-1 cells. Suitable expression vectors for directing expression in mammalian cells generally include a promoter (e.g., derived from viral material such as polyoma, Adenovirus 2, cytomegalovirus, retrovirus (pBabe and LXHSD), and Simian Virus 40), as well as other transcriptional and

translational control sequences. Examples of mammalian expression vectors include pCDM8 (Seed, B., (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987), EMBOJ. 6:187-195).

More particularly, bacterial host cells suitable for carrying out the present invention include *E. coli*, *B. subtilis*, *Salmonella typhimurium*, and various species within the genus' 5 *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, as well as many other bacterial species well known to one of ordinary skill in the art. Suitable bacterial expression vectors preferably comprise a promoter which functions in the host cell, one or more selectable phenotypic markers, and a bacterial origin of replication. Representative promoters include the β -lactamase (penicillinase) and lactose promoter system (see Chang et al., Nature 10 275:615, 1978), the *trp* promoter (Nichols and Yanofsky, Meth in Enzymology 101:155, 1983) and the *tac* promoter (Russell et al., Gene 20: 231, 1982). Representative selectable markers include various antibiotic resistance markers such as the kanamycin or ampicillin resistance genes. Suitable expression vectors include but are not limited to bacteriophages such as lambda derivatives or plasmids such as pBR322 (see Bolivar et al., Gene 2:9S, 1977), the pUC 15 plasmids pUC18, pUC19, pUC118, pUC119 (see Messing, Meth in Enzymology 101:20-77, 1983 and Vieira and Messing, Gene 19:259-268, 1982), and pNH8A, pNH16a, pNH18a, and Bluescript M13 (Stratagene, La Jolla, Calif.). Typical fusion expression vectors which may be used are discussed above, e.g. pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ). Examples of 20 inducible non-fusion expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89).

Yeast and fungi host cells suitable for carrying out the present invention include, but are not limited to *Saccharomyces cerevisiae*, the genera *Pichia* or *Kluyveromyces* and various 25 species of the genus *Aspergillus*. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari. et al., (1987) Embo J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al., (1987) Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA). Protocols for the transformation of yeast and fungi are well known to those of ordinary skill in the art (see Hinnen et al., PNAS USA 75:1929, 30 1978; Itoh et al., J. Bacteriology 153:163, 1983, and Cullen et al. Bio/Technology 5:369, 1987).

Given the teachings provided herein, promoters, terminators, and methods for introducing expression vectors of an appropriate type into plant, avian, and insect cells may also be readily accomplished. For example, within one embodiment, the proteins of the invention may be expressed from plant cells (see Sinkar et al., J. Biosci (Bangalore) 11:47-58, 35 1987, which reviews the use of *Agrobacterium rhizogenes* vectors; see also Zambryski et al., Genetic Engineering, Principles and Methods, Hollaender and Setlow (eds.), Vol. VI, pp. 253-278, Plenum Press, New York, 1984, which describes the use of expression vectors for plant cells, including, among others, pAS2022, pAS2023, and pAS2034).

Insect cells suitable for carrying out the present invention include cells and cell lines from *Bombyx* or *Spodoptera* species. Baculovirus vectors available for expression of proteins in cultured insect cells (SF 9, SF 21, and T.ni-High Five cells) include the pAc series (Smith et al., (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Luckow, V.A., and Summers, M.D., (1989) Virology 170:31-39) and pBAC PAK.

Alternatively, the proteins of the invention may also be expressed in non-human transgenic animals such as mice, rats, rabbits, sheep and pigs (see Hammer et al. (Nature 315:680-683, 1985), Palmiter et al. (Science 222:809-814, 1983), Brinster et al. (Proc Natl. Acad. Sci USA 82:44384442, 1985), Palmiter and Brinster (Cell. 41:343-345, 1985) and U.S. Patent No. 4,736,866).

The invention further provides a recombinant expression vector for the transcription and translation in invertebrate animals including, but not limited to, zebrafish, xenopus and drosophila.

The proteins of the invention may also be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964, J. Am. Chem. Assoc. 85:2149-2154) or synthesis in homogenous solution (Houbenweyl, 1987, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).

N-terminal or C-terminal fusion proteins comprising the SPLICE *erbB-2* protein of the invention conjugated with other molecules, such as proteins may be prepared by fusing, through recombinant techniques, the N-terminal or C-terminal of the protein, and the sequence of a selected protein or selectable marker protein with a desired biological function. The resultant fusion proteins contain the SPLICE *erbB-2* protein fused to the selected protein or marker protein as described herein. Examples of proteins which may be used to prepare fusion proteins include green fluorescent protein (GFP), yellow fluorescent protein, blue fluorescent protein, alkaline phosphatase, immunoglobulins, glutathione-S-transferase (GST), haemagglutinin (HA), and truncated myc.

Phosphorylation or activation SPLICE *erbB-2* proteins of the invention may be ensured using, for example, the method described in Reedijk et al. The EMBO Journal 11(4):1365, 1992.

III. Utility of the Nucleic Acid Molecules and Proteins of the Invention Diagnostic Uses

The nucleic acid molecules of the invention allow those skilled in the art to construct nucleotide probes for use in the detection of nucleic acid sequences in biological materials. Suitable probes include nucleic acid molecules based on nucleic acid sequences encoding at least 6 sequential amino acids from regions of the SPLICE *erbB-2* protein as shown in Figure 2. A nucleotide probe may be labelled with a detectable substance such as a radioactive label which provides for an adequate signal and has sufficient half-life such as ³²P, ³H, ¹⁴C or the like. Other detectable substances which may be used include antigens that are recognized by

a specific labelled antibody, fluorescent compounds, enzymes, antibodies specific for a labelled antigen, and luminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. Labelled probes may be hybridized to nucleic acids on solid supports such as nitrocellulose filters or nylon membranes as generally described in Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual (2nd ed.). The nucleic acid probes may be used to detect genes, preferably in human cells, that encode the SPLICE *erbB-2* protein. The nucleotide probes may be useful in the diagnosis of disorders of cell transformation such as cancer. The nucleotide probes may also be used as a diagnostic tool on tissue biopsies to assess the transformed state of the cell. The probes may also be used in *in situ* hybridization of early embryos to assess both the onset and pattern of expression during development.

SPLICE *erbB-2* proteins of the invention can be used to prepare antibodies specific for the SPLICE *erbB-2* proteins that may be used to detect the protein in a biological sample. Antibodies can be prepared which bind a distinct epitope in an unconserved region of the protein. An unconserved region of the protein is one which does not have substantial sequence homology to other proteins. Antibodies which distinguish between SPLICE *erbB-2* and other *erbB-2* proteins can be prepared which bind distinct epitopes of the protein.

Conventional methods can be used to prepare the antibodies. For example, by using a peptide of the SPLICE *erbB-2* protein, polyclonal antisera or monoclonal antibodies can be made using standard methods. A mammal, (e.g., a mouse, hamster, or rabbit) can be immunized with an immunogenic form of the peptide which elicits an antibody response in the mammal. Techniques for conferring immunogenicity on a peptide include conjugation to carriers or other techniques well known in the art. For example, the protein or peptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassay procedures can be used with the immunogen as antigen to assess the levels of antibodies. Following immunization, antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera.

To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells. Such techniques are well known in the art, (e.g., the hybridoma technique originally developed by Kohler and Milstein (Nature 256, 495-497 (1975)) as well as other techniques such as the human B-cell hybridoma technique (Kozbor et al., Immunol. Today 4, 72 (1983)), the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al. Monoclonal Antibodies in Cancer Therapy (1985) Allen R. Bliss, Inc., pages 77-96), and screening of combinatorial antibody libraries (Huse et al., Science 246, 1275 (1989)). Hybridoma cells can

be screened immunochemically for production of antibodies specifically reactive with the peptide and the monoclonal antibodies can be isolated. Therefore, the invention also contemplates hybridoma cells secreting monoclonal antibodies with specificity for the SPLICE *erbB*-2 protein as described herein.

- 5 The term "antibody" as used herein is intended to include fragments thereof which also specifically react with a SPLICE *erbB*-2 protein, or peptide thereof, having the activity of the SPLICE *erbB*-2 protein. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above. For example, F(ab')₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab')₂ fragment can be treated to reduce disulfide bridges to produce Fab' fragments.
- 10

- Chimeric antibody derivatives, i.e., antibody molecules that combine a non-human animal variable region and a human constant region are also contemplated within the scope of the invention. Chimeric antibody molecules can include, for example, the antigen binding domain from an antibody of a mouse, rat, or other species, with human constant regions.
- 15 Conventional methods may be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes the gene product of SPLICE *erbB*-2 antigens of the invention (See, for example, Morrison et al., Proc. Natl Acad. Sci. U.S.A. 81,6851 (1985); Takeda et al., Nature 314, 452 (1985), Cabilly et al., U.S. Patent No. 4,816,567; Boss et al., U.S. Patent No. 4,816,397; Tanaguchi et al., European Patent Publication EP171496; European Patent Publication 0173494, United Kingdom patent GB 2177096B). It is expected that chimeric antibodies would be less immunogenic in a human subject than the corresponding non-chimeric antibody.
- 20

- Monoclonal or chimeric antibodies specifically reactive with a protein of the invention as described herein can be further humanized by producing human constant region chimeras, in which parts of the variable regions, particularly the conserved framework regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-human origin. Such immunoglobulin molecules may be made by techniques known in the art, (e.g., Teng et al., Proc. Natl. Acad. Sci. U.S.A., 80, 7308-7312 (1983); Kozbor et al., Immunology Today, 4, 7279 (1983); Olsson et al., Meth. Enzymol., 92, 3-16 (1982)), and PCT Publication WO92/06193 or EP 0239400). Humanized antibodies can also be commercially produced (Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.)
- 25
- 30

- Specific antibodies, or antibody fragments, reactive against proteins of the invention may also be generated by screening expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with peptides produced from the nucleic acid molecules of the present invention. For example, complete Fab fragments, VH regions and FV regions can be expressed in bacteria using phage expression libraries (See for example Ward et al., Nature 341, 544-546: (1989); Huse et al., Science 246, 1275-1281 (1989); and McCafferty
- 35

et al. Nature 348, 552-554 (1990)). Alternatively, a SCID-hu mouse, for example the model developed by Genpharm, can be used to produce antibodies, or fragments thereof.

Antibodies specifically reactive with the SPLICE *erbB-2* protein, or derivatives thereof, such as enzyme conjugates or labeled derivatives, may be used to detect SPLICE *erbB-2* protein in various biological materials, for example they may be used in any known immunoassays which rely on the binding interaction between an antigenic determinant of the protein, and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex agglutination, hemagglutination, and histochemical tests. Thus, the antibodies may be used to detect and quantify the SPLICE *erbB-2* protein in a sample in order to determine its role in particular cellular events or pathological states, and to diagnose and treat such pathological states. The antibodies may also be used on biopsied tissue to assess whether or not a cell is transformed.

In particular, antibodies of the invention may be used in immuno-histochemical analyses, for example, at the cellular and sub-subcellular level, to detect the SPLICE *erbB-2* protein, to localise it to particular cells and tissues and to specific subcellular locations, and to quantitate the level of expression.

Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect the SPLICE *erbB-2* protein. Generally, an antibody of the invention may be labelled with a detectable substance and the SPLICE *erbB-2* protein may be localised in tissue based upon the presence of the detectable substance. Examples of detectable substances include various enzymes, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, biotin, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable radioactive material include radioactive iodine I^{125} , I^{131} or tritium. Antibodies may also be coupled to electron dense substances, such as ferritin or colloidal gold, which are readily visualised by electron microscopy.

Indirect methods may also be employed in which the primary antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against a SPLICE *erbB-2* protein. By way of example, if the antibody having specificity against the protein is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labelled with a detectable substance as described herein.

Where a radioactive label is used as a detectable substance, SPLICE *erbB-2* protein may be localized by autoradiography. The results of autoradiography may be quantitated

by determining the density of particles in the autoradiographs by various optical methods, or by counting the grains.

As discussed herein, SPLICE *erbB-2* protein is an *erbB-2* receptor with intracellular tyrosine kinase activity which is constitutively tyrosine phosphorylated having an in frame deletion of 16 amino acids, two of which are conserved cysteine residues. This novel receptor is capable of transforming Rat-1 fibroblasts and as such likely plays a role in regulating transformation of cells. Therefore, the above described methods for detecting nucleic acid molecules and SPLICE *erbB-2* proteins of the invention, can be used to monitor cell transformation. It would also be apparent to one skilled in the art that the above described methods may be used to study the developmental expression of the SPLICE *erbB-2* protein and, accordingly, will provide further insight into the role of the SPLICE *erbB-2* protein in cell development. In addition, since the SPLICE *erbB-2* protein is highly expressed in mammary tumor cells, it may be involved in mammary tissue development or physiology.

Therapeutic Uses

The SPLICE *erbB-2* protein of the invention is likely involved in the regulation of cell signalling pathways that control cell transformation. Accordingly, the present invention provides a method of modulating cell transformation comprising administering an effective amount of a SPLICE *erbB-2* protein or a nucleic acid encoding a SPLICE *erbB-2* protein to a cell or animal in need thereof. The term "effective amount" as used herein means an amount effective, at dosages and for periods of time necessary to achieve the desired results.

In another embodiment, the present invention provides a method of modulating tumor cell proliferation. In a preferred embodiment, the invention provides a method of inhibiting or reducing tumor cell proliferation by administering an agent that inhibits the expression or the biological activity of the SPLICE *erbB-2* protein. Agents that inhibit the activity of a SPLICE *erbB-2* protein include antibodies to the protein. Agents that inhibit the expression of the SPLICE *erbB-2* gene include antisense oligonucleotides to a SPLICE *erbB-2* nucleic acid sequence. Both of these are described above.

In addition to antibodies and antisense oligonucleotides, other substances that inhibit SPLICE *erbB-2* protein expression or activity may also be identified.

Substances which affect SPLICE *erbB-2* protein activity can be identified based on their ability to bind to the SPLICE *erbB-2* protein. Therefore, the invention also provides methods for identifying substances which are capable of binding to a SPLICE *erbB-2* protein. In particular, such methods may be used to identify substances capable of binding to, and in some cases activating (i.e., phosphorylating), or deactivating the protein of the invention.

Substances which can bind with a SPLICE *erbB-2* protein of the invention may be identified by reacting the protein with a substance which potentially binds to the protein, and assaying for complexes, for free substance, or for non-complexed SPLICE *erbB-2* protein, or for activation or deactivation (as the case may be) of the protein. In particular, a yeast two

hybrid assay system may be used to identify proteins which interact with the SPLICE *ERBB-2* protein (Fields, S. and Song, O., 1989, Nature, 340:245-247).

Conditions which permit the formation of a substance and SPLICE *erbB-2* protein complexes may be selected having regard to factors such as the nature and amounts of the
5 substance and the protein.

The substance-protein complex, free substance or non-complexed proteins may be isolated by conventional isolation techniques, for example, salting out, chromatography, electrophoresis, gel filtration, fractionation, absorption, polyacrylamide gel electrophoresis, agglutination, or combinations thereof. To facilitate the assay of the
10 components, antibody against the SPLICE *erbB-2* protein or the substance, or labelled SPLICE *erbB-2* protein, or a labelled substance may be utilized. The antibodies, proteins, or substances may be labelled with a detectable substance as described above.

Substances which bind to and activate or deactivate SPLICE *erbB-2* protein of the invention may be identified by assaying for phosphorylation of the tyrosine residues of the
15 protein.

SPLICE *erbB-2* protein, or the substance used in the method of the invention may be immobilized. For example, the SPLICE *erbB-2* protein or substance may be bound to a suitable carrier. Examples of suitable carriers are agarose, cellulose, dextran, Sephadex, Sepharose, carboxymethyl cellulose polystyrene, filter paper, ion-exchange resin, plastic film, plastic
20 tube, glass beads, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The carrier may be in the shape of, for example, a tube, test plate, beads, disc, sphere etc.

The immobilized protein or substance may be prepared by reacting the material with a suitable insoluble carrier using known chemical or physical methods, for example, cyanogen
25 bromide coupling.

The proteins or substance may also be expressed on the surface of a cell using the methods described herein.

The invention also contemplates a method for assaying for an agonist or antagonist of the binding of the SPLICE *erbB-2* protein with a substance which is capable of binding with
30 the SPLICE *erbB-2* protein. The agonist or antagonist may be an endogenous physiological substance or it may be a natural or synthetic substance. Substances which are capable of binding with the SPLICE *erbB-2* protein may be identified using the methods set forth herein.

It will be understood that the agonists and antagonists that can be assayed using the
35 methods of the invention may act on one or more of the binding sites on the protein or substance including agonist binding sites, competitive antagonist binding sites, non-competitive antagonist binding sites or allosteric sites.

The invention also makes it possible to screen for antagonists that inhibit the effects of an agonist of the interaction of the SPLICE *erbB-2* protein with a substance which is capable of binding to the protein. Thus, the invention may be used to assay for a substance that competes for the same binding site of the SPLICE *erbB-2* protein.

5 The methods described above may be used to identify a substance which is capable of binding to an activated SPLICE *erbB-2* protein, and to assay for an agonist or antagonist of the binding of activated protein, with a substance which is capable of binding with activated SPLICE *erbB-2* protein. An activated (i.e., phosphorylated) SPLICE *erbB-2* protein may be prepared using the methods described (for example in Reedijk et al. The
10 EMBO Journal, 11(4):1365, 1992) for producing a constitutively tyrosine phosphorylated protein.

It will also be appreciated that intracellular substances which are capable of binding to SPLICE *erbB-2* protein may be identified using the methods described herein.

The invention further provides a method for assaying for a substance that affects an
15 SPLICE *erbB-2* protein regulatory pathway comprising administering to a non-human animal or to a tissue of an animal, a substance suspected of affecting a SPLICE *erbB-2* protein regulatory pathway, and quantitating the protein or nucleic acids encoding the protein, or examining the pattern and/or level of expression of SPLICE *erbB-2* protein, in the non-human animal or tissue. SPLICE *erbB-2* protein may be quantitated and its expression may be
20 examined using the methods described herein.

Substances identified by the methods described herein, may be used for modulating SPLICE *erbB-2* protein regulatory pathways and accordingly may be used in the treatment of conditions involving perturbation of SPLICE *erbB-2* protein signalling pathways. In particular, the substances may be particularly useful in the treatment of disorders of cell
25 proliferation such as cancer.

As stated previously, SPLICE *erbB-2* protein is involved in cell transformation and inhibitors of this protein may be useful in reversing disorders involving cell transformation such as cancer. In contrast, stimulators of the SPLICE *erbB-2* protein may be useful in the treatment of disorders requiring stimulation of proliferation. Accordingly, substances that
30 stimulate SPLICE *erbB-2* protein (for example, identified using the methods of the invention) may be used to stimulate cell proliferation. Substances which stimulate cell proliferation may be useful in the treatment of conditions involving damaged cells including conditions in which degeneration of tissue occurs such as arthropathy, bone resorption, inflammatory disease, degenerative disorders of the central nervous system and for promoting wound
35 healing.

Pharmaceutical Compositions

All of the above described substances (such as the SPLICE *erbB-2* protein, the nucleic acid encoding such protein, antibodies to such protein, antisense oligonucleotides to the

nucleic acid molecules and substances that modulate SPLICE *erbB-2* protein activity) may be formulated into pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration *in vivo*. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the substance to be administered in which any toxic effects are outweighed by the therapeutic effects. The substances may be administered to living organisms including humans, and animals. In this context and throughout this specification animal means any member of the animal kingdom. Administration of a therapeutically active amount of pharmaceutical compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of antibody to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

Active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound. If the active substance is a nucleic acid encoding a SPLICE *erbB-2* protein or an antisense oligonucleotide it may be delivered using techniques known in the art. Recombinant molecules comprising an antisense sequence or oligonucleotide may be directly introduced into cells or tissues *in vivo* using delivery vehicles such as retroviral vectors, adeno viral vectors and DNA virus vectors. They may also be introduced using physical techniques such as microinjection and electroporation or chemical methods such as co-precipitation and incorporation of DNA into liposomes.

The compositions described herein can be prepared by ~~per se~~ known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

Reagents suitable for applying methods of the invention to identify substances that affect SPLICE *erbB-2* protein may be packaged into convenient kits providing the necessary

materials packaged into suitable containers. The kits may also include suitable supports useful in performing the methods of the invention.

Experimental Models

The invention also provides methods for studying the function of SPLICE *erbB-2* protein. Cells, tissues and non-human animals that express or over-express SPLICE *erbB-2* protein may be prepared by transfecting cells, tissues or oocytes (to prepare transgenic animals) with a recombinant expression vector of the invention (as described previously). In particular, transgenic technology (via nuclear oocyte microinjection of naked DNA) will assay the effect of over expression or alterations of the SPLICE *erbB-2* protein expression in various developmental systems, including bone development, neurogenesis, mammary development, lung epithelial development.

Cells, tissues, and non-human animals lacking in SPLICE *erbB-2* protein expression or partially lacking in SPLICE *erbB-2* protein expression may be developed using recombinant expression vectors of the invention having specific deletion or insertion mutations in the SPLICE *erbB-2* gene. A recombinant expression vector may be used to inactivate or alter the endogenous gene by homologous recombination, and thereby create a SPLICE *erbB-2* protein deficient cell, tissue or animal.

Null alleles may be generated in cells, such as embryonic stem cells by deletion mutation. A recombinant SPLICE *erbB-2* gene may also be engineered to contain an insertion mutation which inactivates the SPLICE *erbB-2* protein. Such a construct may then be introduced into a cell, such as an embryonic stem cell, by a technique such as transfection, electroporation, injection etc. Cells lacking an intact SPLICE *erbB-2* gene may then be identified, for example by Southern blotting, Northern Blotting or by assaying for SPLICE *erbB-2* protein using the methods described herein. Such cells may then be fused to embryonic stem cells to generate transgenic non-human animals deficient in SPLICE *erbB-2* protein. Germline transmission of the mutation may be achieved, for example, by aggregating the embryonic stem cells with early stage embryos, such as 8 cell embryos, *in vitro*; transferring the resulting blastocysts into recipient females and; generating germline transmission of the resulting aggregation chimeras. Such a mutant animal may be used to define specific cell populations, developmental patterns and *in vivo* processes, normally dependent on SPLICE *erbB-2* protein expression.

The present invention also includes the preparation of tissue specific knock-outs of the SPLICE *erbB-2* gene.

EXAMPLES

EXAMPLE 1

Cloning and Sequencing of SPLICE *erbB-2* Gene/Protein

DNA constructions

5 Expression plasmids containing various human *erbB-2* cDNAs were constructed by inserting each cDNA as a *Hind* III fragment into the corresponding site of pJ4 Ω . The cDNAs encoding both wild-type and activated *erbB-2* (valine to glutamic acid substitution in the transmembrane domain) were generous gifts of Nancy E. Hynes (Friedrich Miescher Institute, Basel, Switzerland). The *erbB-2* (ECD DEL) mutant was generated by
10 oligonucleotide-directed mutagenesis and the *erbB-2* (SPLICE) mutation was amplified from human breast tumor RNA. The polymerase chain reaction (PCR) products were sequenced to ensure that only the desired mutations were present.

 The sequence of the cDNA is shown in Figure 1 and SEQ.ID.NO. 1. The amino acid sequence is shown in Figure 2 and SEQ.ID.NO. 2.

15 EXAMPLE 2

RT-PCR of total RNA from Normal and Tumor Breast Tissue

Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)

 The reverse transcription reaction was performed using total RNA isolated from a human prostate carcinoma cell line (DU145) as previously described (Siegel *et al.*, 1994).
20 After incubation at 37°C for 2 h, 1.0 μ l of the RT mix was added to the following: 0.5 μ l of each oligonucleotide primer (10 μ M), 2.0 μ l of 10X PCR buffer (200 mM Tris-HCl [pH 8.4], 500 mM KCl), 1.0 μ l of 50 mM MgCl₂, 1.0 μ l of deoxynucleotide triphosphate (dNTP) mix (10mM [each] dATP, dCTP, dGTP, and dTTP), 1.0 μ l of [α -³²P]dCTP (10 μ Ci) and distilled water to bring the final volume to 20.0 μ l. The reaction mixture was overlaid with 10.0 μ l of paraffin
25 oil and heated to 95°C for 5 min. The temperature was dropped to 80°C for 2 min and 5.0 μ l of the following mixture was added to each sample: 0.1 μ l of *Taq* DNA polymerase (GIBCO BRL), 0.5 μ l of 10X PCR buffer, and 4.4 μ l of distilled water. PCR amplification was performed for 30 cycles of 1 min at 94°C, 30 s at 55°C, and 1 min at 72°C. Both the wild-type and alternately spliced form of *erbB-2* were amplified with the following primers; AB12904
30 (TTTCCAGATGAGGAGGGC) (SEQ. I.D. NO. 3) and AB12903 (CGGAATTCCTGTCACCAGCTGCACCGT) (SEQ. I.D. No. 4), which amplify the region corresponding to nucleotides 1996-2544 of the human *erbB-2* cDNA (Coussens *et al.*, 1985).

 Inspection of the intron/exon structure of both the murine and human *erbB-2* genomic loci revealed that an in-frame deletion could result from the removal of an exon immediately
35 preceding the transmembrane domain (see Figure 3a). This alternatively spliced product would contain a deletion that closely resembles the transgene deletions observed in the MMTW wild-type *neu* transgenic mice (Figure 3b). To assess whether this putative splice form could be detected in human breast tumors, total RNA derived from both normal human

breast tissue and tumor samples were subjected to reverse transcriptase/polymerase chain reaction (RT-PCR) with oligonucleotide primers flanking the region of interest. The results of these analyses revealed that both normal and tumor tissue displayed evidence of the spliced transcript (Figure 3c). Direct sequence analyses of selected RT-PCR products confirmed that
5 this altered spliced form possessed the expected 16 amino acid in-frame deletion (Figure 3b).

EXAMPLE 3

Transformation of Rat-1 Fibroblasts

Cell culture and Focus assays

Rat-1 fibroblasts were maintained in Dulbecco's modified Eagle's medium (DMEM)
10 supplemented with 10% fetal bovine serum (FBS), penicillin, streptomycin, and fungizone (GIBCO BRL). Stable cell lines were derived by electroporation as described previously (Siegel *et al.*, 1994). DNA was introduced into the Rat-1 cells at a 50:1 ratio of expression plasmid to puromycin resistance plasmid (PGK-puro) and resistant colonies were selected for 10 days in media containing puromycin (3.0 µg/ml) prior to deriving clonal cell lines.

15 The *erbB-2* focus assays were performed essentially as described (Siegel *et al.*, 1994) with the exception that monolayers were maintained for 12 days in DMEM supplemented with 2% FBS, penicillin, streptomycin, and fungizone. Five µg of each pJ4Ω expression plasmid was electroporated per 1x10⁶ cells.

Given the resemblance of the spliced form of the *erbB-2* to the sporadic deletions
20 that occur during mammary tumorigenesis in MMTW wild-type *neu* mice, we compared the specific transforming activity of this spliced form to two previously characterized transforming alleles of *erbB-2*. To accomplish this, expression plasmids bearing the wild-type (WT) *erbB-2* cDNA, a transforming *erbB-2* allele possessing the point mutation in the transmembrane domain (VE), a previously characterized sporadic deletion discovered in the
25 *neu* proto-oncogene (Siegel *et al.*, 1994) (ECD DEL) or the spliced form of *erbB-2* (SPLICE) were electroporated into Rat-1 cells and assessed for their capacity to induce transformed foci (Figure 4a). Whereas expression of wild-type *erbB-2* failed to transform Rat-1 fibroblasts, expression of the spliced form and the two previously characterized transforming alleles resulted in the induction of transformed foci (Figure 4b). Comparison of the specific
30 transforming activity of the spliced form *erbB-2* revealed that it transformed at 26% of the level observed with the transmembrane mutant of *erbB-2* (VE) (Table 1). The spliced form of *erbB-2* was similar in its transforming activity to the previously characterized sporadic deletion (ECD DEL) (Table 1). Taken together, these observations suggest that the
35 alternative spliced form of *erbB-2* may represent a causative factor in the induction of human breast tumors.

EXAMPLE 4

Tyrosine Phosphorylation of Altered *erbB-2* Receptors

Immunoprecipitation and immunoblotting

Lysates from established cell lines were prepared from 10 cm tissue culture plates once the cells had reached confluence. The cells were washed twice in ice cold 1XPBS (140 mM NaCl, 2.7 mM KCl, 4.3 mM Na₂HPO₄, 1.4 mM KH₂PO₄) and lysed for 20 min on ice in TNE lysis buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1% Nonidet P-40, 2 mM EDTA [pH 8.0], 1 mM sodium orthovanadate, 10 mM sodium fluoride, 10 µg/ml Aprotinin, 10 µg/ml Leupeptin). Lysates were cleared by centrifugation for 10 min at 4°C and the protein concentration determined by Bradford assay (Bio-Rad).

Protocols for both immunoprecipitation and immunoblot analysis have been described in detail elsewhere (Muthuswamy *et al.*, 1994). ErbB-2 was immunoprecipitated (Ab-5; 1 µg/600 µg total protein) and blotted (Ab-3; 1:1000) using mouse monoclonal antibodies purchased from Oncogene Research Products, Inc. Phosphotyrosine blots were probed with mouse anti-phosphotyrosine antibodies (PY20; 1:1000) obtained from Transduction Laboratories. Horseradish peroxidase conjugated anti-mouse secondary antibodies (1:2500) (Jackson Laboratories) were used in each case.

To determine whether the oncogenic potential of the spliced form of *erbB-2* was related to activation of the receptor's catalytic activity, established Rat-1 cells expressing various *erbB-2* alleles were generated. To assess the state of tyrosine phosphorylation of the receptor, protein extracts derived from the various cell lines were immunoprecipitated with *erbB-2* specific antibodies and subjected to immunoblot analyses with anti-phosphotyrosine antibodies. As shown in Figure 5a, tyrosine phosphorylated *erbB-2* could be easily detected in transformed cells expressing the oncogenic alleles of *erbB-2* but was barely detectable in morphologically normal cell lines expressing elevated levels of wild-type *erbB-2*. A parallel immunoblot for *erbB-2* revealed that all of the established cell lines expressed similar levels of the receptor (Figure 5b). These observations argue that the oncogenic activation of *erbB-2* reflects an increase in its catalytic activity, as measured by the extent of tyrosine phosphorylation.

DISCUSSION

The observation that an alternatively spliced form of *erbB-2* is expressed in a large portion of human breast cancers has important implications in our understanding the molecular basis of this prevalent human malignancy. Consistent with the concept that alternate splicing may play a role in the activation of receptor tyrosine kinases (RTKs), it has been reported that a spliced form of the Ron RTK carries a similar cysteine deletion that leads to its oncogenic activation (Collesi *et al.*, 1996). Moreover, deletions in the EGFR (Sugawa *et al.*, 1990; Wong *et al.*, 1992) and missense mutations in RET (Mulligan *et al.*, 1993) which also affect cysteine residues situated in the extracellular domains of these RTKs, have frequently been observed in human gliomas and endocrine neoplasias, respectively. In each case, the observed mutations serve to activate the transforming ability of these receptors (Nishikawa *et al.*, 1994; Santoro *et al.*, 1995; Asai *et al.*, 1995). Taken together,

these observations suggest that this mechanism of RTK activation may occur frequently in human malignancies. Therapeutic reagents specific to the receptor encoded by this spliced form of *erbB-2* may have important diagnostic and therapeutic implications in the treatment of human breast cancer.

DETAILED LEGENDS TO FIGURES 3, 4 AND 5**FIGURE 3**

Alternate mRNA splicing results in an *erbB-2* transcript harboring an in-frame deletion. (a) Schematic representation of a small region of the human *erbB-2* genomic locus indicating the exon-intron boundaries. The values indicated above the schematic represent nucleotide numbers corresponding to the cDNA. Uppercase letters designate coding sequences whereas nucleotides within the introns are in lower case letters. The aberrant splicing event leading to the deletion of an exon (grey) is indicated by the dashed lines. (b) An alignment of the wild-type and alternatively spliced *erbB-2* messages indicating the sequences removed by the aberrant splicing event (grey box). Reverse-transcriptase polymerase chain reaction (RT-PCR) analysis of both normal breast and tumor tissue. The negative control represents an RT-PCR performed in the absence of RNA (distilled water). The PCR was conducted in the presence of [a32P]dCTP and the products resolved on a 5% polyacrylamide gel, dried and exposed to film. The position of the wild-type and spliced products are indicated.

FIGURE 4

Expression of altered ErbB-2 receptors results in morphological transformation. (a) Partial amino acid sequence alignment of the wild-type and altered ErbB-2 receptors tested in Rat-1 focus assays. ErbB-2 (WT) represents the wild-type receptor, ErbB-2 (VE) possesses a valine to glutamic acid point mutation in the transmembrane domain, ErbB-2 (ECD DEL) harbors a deletion which mimics a previously characterized mutation in the Neu receptor (Siegel et al, 1994; Siegel and Muller, 1996), and ErbB-2 (SPLICE) contains the deletion encoded by the alternatively spliced *erbB-2* message. A portion of the transmembrane domain is indicated by the open box and designated TM. The asterisk indicates the position of the valine to glutamic acid substitution in ErbB-2 (VE). (b) Shown are representative plates from focus assay #1 (see Table 1) illustrating the relative transforming abilities of the various forms of ErbB-2 indicated in (a).

FIGURE 5

Altered ErbB-2 receptors are constitutively tyrosine phosphorylated when expressed in Pat-1 cells. (a) Lysates from stable cell lines expressing wild-type ErbB-2 (WT) or the three altered receptors (VE, ECD, SPLICE) were immunoprecipitated for ErbB-2 (Ab5, Oncogene Research Products) and the immunoprecipitates were subjected to immunoblot analysis with phosphotyrosine-specific antibodies (PY20, Transduction Laboratories). (b) Lysates from stable cell lines expressing the various ErbB-2 receptors were immunoprecipitated for ErbB-2 (Ab5, Oncogene Research Products) and the immunoprecipitates were subjected to immunoblot analysis with ErbB-2/Neu-specific antibodies (AW, Oncogene Research Products). In each panel, Rat1 indicates the parental cell line which does not contain any of the *erbB-2* expression plasmids. The position of ErbB-2 is indicated in each panel by the arrow.

Having illustrated and described the principles of the invention in a preferred embodiment, it should be appreciated to those skilled in the art that the invention can be modified in arrangement and detail without departure from such principles. We claim all modifications coming within the scope of the following claims.

- 5 All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

FULL CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION

1. Asai, N., T. Washita, M. Matsuyama and M. Takahashi. 1995. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. *Mol. Cell. Biol.* 15:1613-1619.
- 5 2. Collesi, C., M. M. Santoro, G. Gaudino and P. M. Comoglio. 1996. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. *Mol. Cell. Biol.* 16:5518-5526.
3. Guy, C. T., R. D. Cardiff and W. J. Muller. 1996. Activated *neu* induces rapid tumor progression. *J. Biol. Chem.* 271:7673-7678.
- 10 4. Guy, C. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff and W. J. Muller. 1992. Expression of the *neu* protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. *Proc. Natl. Acad. Sci. USA* 89:10578-10582.
5. Hynes, N. E. and D. F. Stern. 1994. The biology of *erbB-2/neu/HER-2* and its role in cancer. *Biochim. Biophys. Acta* 1198:165-184.
- 15 6. Muller, W. J., E. Sinn, P. K. Pattengale, R. Wallace and P. Leder. 1988. Single step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. *Cell* 54:105-115.
7. Mulligan, L. M., J. B. J. Kwok, C. S. Healey, M. I. Elsdon, C. Eng, E. Gardner, D. R. Love, S. E. Mole, J. K. Moore, L. Papi, M. A. Ponder, H. Telenius, A. Tunnacliffe and B. A. J. Ponder. 1993. Germ-line mutations of the *PET* proto-oncogene in multiple endocrine neoplasia type 2A. *Nature* 363:458-460.
- 20 8. Nishikawa, R., X.-D. Ji, R. C. Harmon, C. S. Lazar, G. N. Gill, W. K. Cavanee and H.-J. Su Huang. 1994. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. *Proc. Natl. Acad. Sci. USA* 91:7727-7731.
- 25 9. Santoro, M., F. Carlomagno, A. Romano, D. P. Bottaro, N. A. Dathan, M. Grieco, A. Fusco, G. Vecchio, B. Matoskova, M. H. Kraus and P. P. DiFlore. 1995. Activation of *RET* as a dominant transforming gene by germline mutations of *MEN2A* and *MEN2B*. *Science* 267:381-383.
10. Siegel, P. M., D. L. Dankort, W. R. Hardy and W. J. Muller. 1994. Novel activating mutations in the *neu* proto-oncogene involved in induction of mammary tumors. *Mol. Cell. Biol.* 14:7068-7077.
- 30 11. Siegel, P. M. and W. J. Muller. 1996. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. *Proc. Natl. Acad. Sci. USA* 93:8878-8883.
- 35 12. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with the amplification of the *HER-2/neu* oncogene. *Science* 235:177-182.

13. Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich and M. F. Press. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 244:707-712.
14. Sugawa, N., A. J. Ekstrand, C. D. James and V. P. Collins. 1990. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human gliomas. *Proc. Natl. Acad. Sci. USA* 87:8602-8606.
15. Wong, A. J., J. M. Ruppert, S. H. Bigner, C. H. Grzeschik, P. A. Humphrey, D. S. Bigner and B. Vogelstein. 1992. Structural alterations of the epidermal growth factor receptor gene in human gliomas. *Proc. Natl. Acad. Sci. USA* 89:2965-2969.
- 10 16. Coussens, L., Yang-Feng, T.L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P.H., Libermann, T.A., Schlessinger, J., Francke, U., Levinson, A. and Ullrich, A. (1985) Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with *neu* Oncogene. *Science*, 230, 1132-1139.
17. Muthuswamy, S.K., Siegel, P.M., Dankort, D.L., Webster, M.A. and Muller, W.J. (1994) Mammary tumors expressing the *neu* proto-oncogene possess elevated c-Src tyrosine kinase activity. *Mol. Cell. Biol.*, 14, 735-743.
- 15

- 30 -

Table 1. Transformation of Rat-1 cells by altered ErbB-2 receptors.

Expression Plasmid ^a	Focus Assay #1		Focus Assay #2		Focus Assay #3		Relative Transforming ability ^d (%)
	Average No. of foci/plate ^b	% Transform. of pJ4QB2(VE) ^c	Average No. of foci/plate ^b	% Transform. of pJ4QB2(VE) ^c	Average No. of foci/plate ^b	% Transform. of pJ4QB2(VE) ^c	
pJ4QB2 (WT)	0	0	0	0	0	0	0
pJ4QB2 (VE)	284±15	100	523±28	100	672±13	100	100±0
pJ4QB2 (ECD DEL)	63±6	22	130±16	25	195±14	29	25±4
pJ4QB2 (SPLICE)	73±8	26	127±15	24	194±14	29	26±3

Three independent focus assays were performed with established Rat-1 fibroblasts. The first two experiments were conducted with plasmid DNA from the same large-scale preparation, while the third experiment was performed with DNA obtained from an independent plasmid preparation. The Rat-1 fibroblasts were maintained in a monolayer for 14 days following electroporation at which time they were stained with Gelmsa.

^a All cDNAs placed under the transcriptional control of the Moloney murine leukemia virus long terminal repeat (Mo-MuLV LTR).

^b Values listed represent the mean number of foci counted on 8 plates ± the standard deviations.

^c Values represent the ratio of the mean number of foci obtained for each construct with respect to pJ4QB2(VE).

^d Values listed represent the mean transforming abilities from all three experiments ± the standard deviations.

WE CLAIM:

1. A purified and isolated nucleic acid molecule comprising a sequence encoding an *erbB-2* receptor protein with an in frame deletion of 16 amino acids two of which are cysteine residues (SPLICE *erbB-2* protein).
- 5 2. A purified and isolated nucleic acid molecule according to claim 1 wherein the protein is constitutively tyrosine phosphorylated.
3. A purified and isolated nucleic acid molecule as claimed in claim 1, comprising (i) a nucleic acid sequence encoding a SPLICE *erbB-2* protein having the amino acid sequence according to Seq.ID.No.2 and, (ii) nucleic acid sequences complementary to (i).
- 10 4. A purified and isolated nucleic acid molecule as claimed in claim 1, comprising
 - (i) a nucleic acid sequence encoding a SPLICE *erbB-2* protein having the nucleic acid sequence according to Seq. ID.No.1 wherein T can also be U;
 - (ii) a nucleic acid sequence complementary to (i);
 - (iii) a nucleic acid molecule differing from any of the nucleic acids of (i) and (ii) in
- 15 codon sequences due to the degeneracy of the genetic code.
5. A purified and isolated nucleic acid molecule comprising a sequence which hybridizes to the nucleic acid molecule as claimed in claim 3.
6. A recombinant expression vector adapted for transformation of a host cell comprising a nucleic acid molecule as claimed in claim 1 and one or more transcription and translation
- 20 elements operatively linked to the nucleic acid molecule.
7. A host cell containing a recombinant expression vector as claimed in claim 6.
8. A method for preparing a SPLICE *erbB-2* protein comprising (a) transferring a recombinant expression vector as claimed in claim 6 into a host cell; (b) selecting transformed host cells from untransformed host cells; (c) culturing a selected transformed host cell under
- 25 conditions which allow expression of the protein; and (d) isolating the protein.
9. A purified and isolated SPLICE *erbB-2* protein.
10. The purified and isolated protein according to claim 9 wherein the protein is constitutively tyrosine phosphorylated.

11. A purified and isolated protein as claimed in claim 9 or 10, which has an amino acid sequence according to Seq.ID.No. 2, or a fragment, analog or derivative thereof.
12. A method of modulating cell transformation comprising administering an effective amount of a SPLICE *erbB-2* protein or a nucleic acid encoding a SPLICE *erbB-2* protein to a cell
5 or animal.
13. A method according to claim 12 wherein the protein has the amino acid sequence according to Seq.ID.NO 2 or a fragment thereof.
14. A method according to claim 12 or 13 wherein the nucleic acid molecule encoding the protein has the sequence according to Seq.ID.NO.1.
- 10 15. A method of inhibiting or reducing cell transformation comprising administering an antisense molecule that is complimentary to a nucleic acid molecule encoding a SPLICE *erbB-2* protein.
16. The method of claim 15 wherein the cell transformation occurs in breast tissue.
17. A method of modulating SPLICE *erbB-2* activity comprising administering an
15 effective amount of inhibitor of SPLICE *erbB-2* protein activity to a cell or animal in need thereof.
18. A method according to claim 17 wherein the inhibitor is selected from the group consisting of antibodies to the SPLICE *erbB-2* protein and antisense oligonucleotides complimentary to a portion of a nucleic acid sequence encoding the SPLICE *erbB-2* protein.
- 20 19. A method according to claim 18 wherein the modulation is inhibition of cancer cell growth in breast tumors.
20. A method for identifying a substance which is capable of binding to a SPLICE *erbB-2* protein or inactive form thereof, comprising the following steps:
- 25 (i) reacting the SPLICE *erbB-2* protein, or inactivated form, with at least one substance which potentially can bind with the SPLICE *erbB-2* protein or an inactivated form thereof, under conditions which permit the formation of complexes between the substance and the protein or an inactivated form thereof; and

(ii) assaying for complexes, for free substance, for non-complexed SPLICE *erbB-2* protein or for activation of SPLICE *erbB-2*

21. A method for assaying a medium for the presence of an agonist or antagonist of the interaction of a SPLICE *erbB-2* protein or an activated form thereof, and a substance which
5 binds to the protein or an activated form thereof comprising the steps of:

(i) combining a known concentration of a SPLICE *erbB-2* protein, with a substance which is capable of binding to the protein and a suspected agonist or antagonist substance under conditions which permit the formation of complexes between the substance and SPLICE *erbB-2* protein;

- 10 (ii) assaying for complexes, free substance, non-complexed SPLICE *erbB-2* protein, or for activation of the protein.

1/8

FIGURE 1

[illegible]

2/8

FIGURE 1 (cont'd)

TGCCACCCCTGAGTGTGACCCCCAGAATGGCTCAGTGACCTGTTTTGGACCGGAGGCTGAC
CAGTGTGTGGCCTGTGCCCACCTATAAGGACCCCTCCCTTCTGCGTGGCCCGCTGCCCCAGC
GGTGTGAAACCTGACCTCTCCTACATGCCCATCTGGAAGTTTCCAGATGAGGAGGGCGCA
TGCCAGCCTTGCCCCATCAACTGCACCCACTC-----
-----CCCTCTGACGTCCATCATCTCTGCGGTGGTTGGCATTTCTG
CTGGTCGTGGTCTTGGGGGTGGTCTTTGGGATCCTCATCAAGCGACGGCAGCAGAAGATC
CGGAAGTACACGATGCGGAGACTGCTGCAGGAAACGGAGCTGGTGGAGCCGCTGACACCT
AGCGGAGCGATGCCCAACCAGGCGCAGATGCGGATCCTGAAAGAGACGGAGCTGAGGAAG
GTGAAGGTGCTTGGATCTGGCGCTTTTGGCACAGTCTACAAGGGCATCTGGATCCCTGAT
GGGGAGAATGTGAAAATTCCAGTGGCCATCAAAGTGTGAGGGAAAACACATCCCCCAA
GCCAACAAAGAAATCTTAGACGAAGCATACGTGATGGCTGGTGTGGGCTCCCCATATGTC
TCCCGCCTTCTGGGCATCTGCCTGACATCCACGGTGCAGCTGGTGACACAGCTTATGCCC
TATGGCTGCCTCTTAGACCATGTCCGGGAAAACCGCGGACGCCTGGGCTCCCAGGACCTG
CTGAAC TGGTGTATGCAGATTGCCAAGGGGATGAGCTACCTGGAGGATGTGCGGCTCGTA
CACAGGGACTTGGCCGCTCGGAACGTGCTGGTCAAGAGTCCCAACCATGTCAA AATTACA
GACTTCGGGCTGGCTCGGCTGCTGGACATTGACGAGACAGAGTACCATGCAGATGGGGGC
AAGGTGCCCATCAAGTGGATGGCGCTGGAGTCCATTCTCCGCCGGCGGTTCACCCACCAG
AGTGATGTGTGGAGTTATGGTGTGACTGTGTGGGAGCTGATGACTTTTGGGGCCAAACCT
TACGATGGGATCCCAGCCCGGGAGATCCCTGACCTGCTGGAAAAGGGGGAGCGGCTGCCC
CAGCCCCCATCTGCACCATTTGATGTCTACATGATCATGGTCAAATGTTGGATGATTGAC
TCTGAATGTGCGCCAAGATTCCGGGAGTTGGTGTCTGAATTCTCCCGCATGGCCAGGGAC
CCCCAGCGCTTTGTGGTCATCCAGAATGAGGACTTGGGGCCAGCCAGTCCCTTGGACAGC
ACCTTCTACCGCTCACTGCTGGAGGACGATGACATGGGGGACCTGGTGGATGCTGAGGAG
TATCTGGTACCCCAGCAGGGCTTCTTCTGTCCAGACCCTGCCCCGGGCGCTGGGGGCATG
GTCCACCACAGGCACCGCAGCTCATCTACCAGGAGTGGCGGTGGGGACCTGACACTAGGG
CTGGAGCCCTCTGAAGAGGAGGCCCCCAGGTCTCCACTGGCACCCCTCCGAAGGGGCTGGC
TCCGATGTATTTGATGGTGACCTGGGAATGGGGGCAGCCAAGGGGCTGCAAAGCCTCCCC
ACACATGACCCCAGCCCTCTACAGCGGTACAGTGAGGACCCACAGTACCCCTGCCCTCT
GAGACTGATGGCTACGTTGCCCCCTGACCTGCAGCCCCCAGCCTGAATATGTGAACCAG
CCAGATGTTGCGCCCCAGCCCCCTTCGCCCCGAGAGGGCCCTCTGCCTGCTGCCCCGACCT

3/8

FIGURE 1 (cont'd)

GCTGGTGCCACTCTGGAAAGGCCCAAGACTCTCTCCCCAGGGAAGAATGGGGTCGTCAAA
GACGTTTTTGCCTTTGGGGGTGCCGTGGAGAACCCCGAGTACTTGACACCCCAGGGAGGA
GCTGCCCCCTCAGCCCCACCTCCTCCTGCCTTCAGCCCAGCCTTCGACAACCTCTATTAC
TGGGACCAGGACCCACCAGAGCGGGGGGCTCCACCCAGCACCTTCAAAGGGACACCTACG
GCAGAGAACCCAGAGTACCTGGGTCTGGACGTGCCAGTGTGAaccagaaggccaagtccg
cagaagccctgatgtgtcctcagggagcaggggaaggcctgacttctgctggcatcaagag
gtgggagggccctccgaccacttccaggggaacctgccatgccaggaacctgtcctaagg
aaccttccttcctgcttgagttcccagatggctggaaggggtccagcctcgttggaagag
gaacagcactgggggagtctttgtggattctgaggccctgcccgaatgagactctaggggtcc
agtggatgccacagcccagcttgccctttccttccagatcctgggtactgaaagcctta
gggaagctggcctgagaggggaagcggccctaaggagtggtctaagaacaaaagcgaccc
attcagagactgtccctgaaacctagtactgcccccatgaggaaggaacagcaatgggtg
tcagtatccaggctttgtacagagtgttttctgttttagtttttacttttttgttttgt
ttttttaagatgaaataaagacccagggggag

4/8

FIGURE 2

L	A	A	L	C	R	W	G	L	L	L	A	L	L	P	P	G	A	A	S
T	Q	V	C	T	G	T	D	M	K	L	R	L	P	A	S	P	E	T	H
L	D	M	L	R	H	L	Y	Q	G	C	Q	V	V	Q	G	N	L	E	L
T	Y	L	P	T	N	A	S	L	S	F	L	Q	D	I	Q	E	V	Q	G
Y	V	L	I	A	H	N	Q	V	R	Q	V	P	L	Q	R	L	R	I	V
R	G	T	Q	L	F	E	D	N	Y	A	L	A	V	L	D	N	G	D	P
L	N	N	T	T	P	V	T	G	A	S	P	G	G	L	R	E	L	Q	L
R	S	L	T	E	I	L	K	G	G	V	L	I	Q	R	N	P	Q	L	C
Y	Q	D	T	I	L	W	K	D	I	F	H	K	N	N	Q	L	A	L	T
L	I	D	T	N	R	S	R	A	C	H	P	C	S	P	M	C	K	G	S
R	C	W	G	E	S	S	E	D	C	Q	S	L	T	R	T	V	C	A	G
G	C	A	R	C	K	G	P	L	P	T	D	C	C	H	E	Q	C	A	A
G	C	T	G	P	K	H	S	D	C	L	A	C	L	H	F	N	H	S	G
I	C	E	L	H	C	P	A	L	V	T	Y	N	T	D	T	F	E	S	M
P	N	P	E	G	R	Y	T	F	G	A	S	C	V	T	A	C	P	Y	N
Y	L	S	T	D	V	G	S	C	T	L	V	C	P	L	H	N	Q	E	V
T	A	E	D	G	T	Q	R	C	E	K	C	S	K	P	C	A	R	V	C
Y	G	L	G	M	E	H	L	R	E	V	R	A	V	T	S	A	N	I	Q
E	F	A	G	C	K	K	I	F	G	S	L	A	F	L	P	E	S	F	D
G	D	P	A	S	N	T	A	P	L	Q	P	E	Q	L	Q	V	F	E	T
L	E	E	I	T	G	Y	L	Y	I	S	A	W	P	D	S	L	P	D	L
S	V	F	Q	N	L	Q	V	I	R	G	R	I	L	H	N	G	A	Y	S
L	T	L	Q	G	L	G	I	S	W	L	G	L	R	S	L	R	E	L	G
S	G	L	A	L	I	H	H	N	T	H	L	C	F	V	H	T	V	P	W
D	Q	L	F	R	N	P	H	Q	A	L	L	H	T	A	N	R	P	E	D
E	C	V	G	E	G	L	A	C	H	Q	L	C	A	R	G	H	C	W	G
P	G	P	T	Q	C	V	N	C	S	Q	F	L	R	G	Q	E	C	V	E
E	C	R	V	L	Q	G	L	P	R	E	Y	V	N	A	R	H	C	L	P
C	H	P	E	C	Q	P	Q	N	G	S	V	T	C	F	G	P	E	A	D
Q	C	V	A	C	A	H	Y	K	D	P	P	F	C	V	A	R	C	P	S
G	V	K	P	D	L	S	Y	M	P	I	W	K	F	P	D	E	E	G	A

5/8


FIGURE 2 (cont'd)

C	Q	P	C	P	I	N	C	T	H	S	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	P	L	T	S	I	I	S	A	V	V	G	I	L
L	V	V	V	L	G	V	V	F	G	I	L	I	K	R	R	Q	Q	K	I
R	K	Y	T	M	R	R	L	L	Q	E	T	E	L	V	E	P	L	T	P
S	G	A	M	P	N	Q	A	Q	M	R	I	L	K	E	T	E	L	R	K
V	K	V	L	G	S	G	A	F	G	T	V	Y	K	G	I	W	I	P	D
G	E	N	V	K	I	P	V	A	I	K	V	L	R	E	N	T	S	P	K
A	N	K	E	I	L	D	E	A	Y	V	M	A	G	V	G	S	P	Y	V
S	R	L	L	G	I	C	L	T	S	T	V	Q	L	V	T	Q	L	M	P
Y	G	C	L	L	D	H	V	R	E	N	R	G	R	L	G	S	Q	D	L
L	N	W	C	M	Q	I	A	K	G	M	S	Y	L	E	D	V	R	L	V
H	R	D	L	A	A	R	N	V	L	V	K	S	P	N	H	V	K	I	T
D	F	G	L	A	R	L	L	D	I	D	E	T	E	Y	H	A	D	G	G
K	V	P	I	K	W	M	A	L	E	S	I	L	R	R	R	F	T	H	Q
S	D	V	W	S	Y	G	V	T	V	W	E	L	M	T	F	G	A	K	P
Y	D	G	I	P	A	R	E	I	P	D	L	L	E	K	G	E	R	L	P
Q	P	P	I	C	T	I	D	V	Y	M	I	M	V	K	C	W	M	I	D
S	E	C	R	P	R	F	R	E	L	V	S	E	F	S	R	M	A	R	D
P	Q	R	F	V	V	I	Q	N	E	D	L	G	P	A	S	P	L	D	S
T	F	Y	R	S	L	L	E	D	D	D	M	G	D	L	V	D	A	E	E
Y	L	V	P	Q	Q	G	F	F	C	P	D	P	A	P	G	A	G	G	M
V	H	H	R	H	R	S	S	S	T	R	S	G	G	G	D	L	T	L	G
L	E	P	S	E	E	E	A	P	R	S	P	L	A	P	S	E	G	A	G
S	D	V	F	D	G	D	L	G	M	G	A	A	K	G	L	Q	S	L	P
T	H	D	P	S	P	L	Q	R	Y	S	E	D	P	T	V	P	L	P	S
E	T	D	G	Y	V	A	P	L	T	C	S	P	Q	P	E	Y	V	N	Q
P	D	V	R	P	Q	P	P	S	P	R	E	G	P	L	P	A	A	R	P
A	G	A	T	L	E	R	P	K	T	L	S	P	G	K	N	G	V	V	K
D	V	F	A	F	G	G	A	V	E	N	P	E	Y	L	T	P	Q	G	G
A	A	P	Q	P	H	P	P	P	A	F	S	P	A	F	D	N	L	Y	Y
W	D	Q	D	P	P	E	R	G	A	P	P	S	T	F	K	G	T	P	T
A	E	N	P	E	Y	L	G	L	D	V	P	V	*						

6/8

FIGURE 3

A



B

WT (Human *erbB-2*)

ACCCACTCTGTGTGGACCTGGATGACAAGGGCTGCCCCCGACAGAGAGCCAGCCCTCTGACGTCC
 T H S C V D L D D K G C P A E Q R A S P L T S

Alternate splice (Human *erbB-2*)

ACCCACTC
 T H S

CCCTCTGACGTCC
 P L T S

C




FIGURE 4


a

ErbB-2 (WT)	:CQPCPINC TM THSCVLDLDDKGC TM PAEQRASPLTSIIISAVVGILLV
ErbB-2 (VE)	:CQPCPINC [*] THSCVLDLDDKGC [*] PAEQRASPLTSIIISAVEGILLV
ErbB-2 (ECD DEL)	:CQPCPINC [*] THSCV
ErbB-2 (SPLICE)	ASPLTSIIISAVVGILLV PLTSIIISAVVGILLV

7/8



b

WT VE ECD DEL SPLICE



8/8

FIGURE 5

a*b*

1 of 12

SEQUENCE LISTING

<110> Muller, William J.
Siegel, Peter M.

<120> Novel Spliced Form of ErbB-2/Neu Oncogene

<130> 3244-012

<140>

<141>

<160> 12

<170> PatentIn Ver. 2.0

<210> 1

<211> 4472

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (175)..(3942)

<400> 1

```

aaggggaggt aaccctggcc cctttggtcg gggccccggg cagccgcgcg ccccttccca 60
cgggggccctt tactgcgcgc cgcgccccggc cccacccct cgcagcacc cgcgccccgc 120
gccctcccag cggggtccag cgggagccat ggggcccggag ccgcagtgag cacc atg 177
                                     Met
                                     1
gag ctg gcg gcc ttg tgc cgc tgg ggg ctc ctc ctc gcc ctc ttg ccc 225
Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu Pro
                    5                      10                      15
ccc gga gcc gcg agc acc caa gtg tgc acc ggc aca gac atg aag ctg 273
Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys Leu
                20                      25                      30
cgg ctc cct gcc agt ccc gag acc cac ctg gac atg ctc cgc cac ctc 321
Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His Leu
                35                      40                      45
tac cag ggc tgc cag gtg gtg cag gga aac ctg gaa ctc acc tac ctg 369
Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr Leu
                50                      55                      60                      65
ccc acc aat gcc agc ctg tcc ttc ctg cag gat atc cag gag gtg cag 417
Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val Gln
                    70                      75                      80
ggc tac gtg ctc atc gct cac aac caa gtg agg cag gtc cca ctg cag 465
Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu Gln
                    85                      90                      95
agg ctg cgg att gtg cga ggc acc cag ctc ttt gag gac aac tat gcc 513
Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr Ala
                100                      105                      110
ctg gcc gtg cta gac aat gga gac ccg ctg aac aat acc acc cct gtc 561
Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro Val
                115                      120                      125

```

2 of 12

aca ggg gcc tcc cca gga ggc ctg cgg gag ctg cag ctt cga agc ctc Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser Leu 130 135 140 145	609
aca gag atc ttg aaa gga ggg gtc ttg atc cag cgg aac ccc cag ctc Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln Leu 150 155 160	657
tgc tac cag gac acg att ttg tgg aag gac atc ttc cac aag aac aac Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn Asn 165 170 175	705
cag ctg gct ctc aca ctg ata gac acc aac cgc tct cgg gcc tgc cac Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys His 180 185 190	753
ccc tgt tct ccg atg tgt aag ggc tcc cgc tgc tgg gga gag agt tct Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser Ser 195 200 205	801
gag gat tgt cag agc ctg acg cgc act gtc tgt gcc ggt ggc tgt gcc Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys Ala 210 215 220 225	849
cgc tgc aag ggg cca ctg ccc act gac tgc tgc cat gag cag tgt gct Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys Ala 230 235 240	897
gcc ggc tgc acg ggc ccc aag cac tct gac tgc ctg gcc tgc ctc cac Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu His 245 250 255	945
ttc aac cac agt ggc atc tgt gag ctg cac tgc cca gcc ctg gtc acc Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val Thr 260 265 270	993
tac aac aca gac acg ttt gag tcc atg ccc aat ccc gag ggc cgg tat Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg Tyr 275 280 285	1041
aca ttc ggc gcc agc tgt gtg act gcc tgt ccc tac aac tac ctt tct Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu Ser 290 295 300 305	1089
acg gac gtg gga tcc tgc acc ctc gtc tgc ccc ctg cac aac caa gag Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln Glu 310 315 320	1137
gtg aca gca gag gat gga aca cag cgg tgt gag aag tgc agc aag ccc Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys Pro 325 330 335	1185
tgt gcc cga gtg tgc tat ggt ctg ggc atg gag cac ttg cga gag gtg Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu Val 340 345 350	1233
agg gca gtt acc agt gcc aat atc cag gag ttt gct ggc tgc aag aag Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys Lys 355 360 365	1281
atc ttt ggg agc ctg gca ttt ctg ccg gag agc ttt gat ggg gac cca Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp Pro 370 375 380 385	1329
gcc tcc aac act gcc ccg ctc cag cca gag cag ctc caa gtg ttt gag Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe Glu 390 395 400	1377

3 of 12

act ctg gaa gag atc aca ggt tac cta tac atc tca gca tgg ccg gac	1425
Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro Asp	
405 410 415	
agc ctg cct gac ctc agc gtc ttc cag aac ctg caa gta atc cgg gga	1473
Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg Gly	
420 425 430	
cga att ctg cac aat ggc gcc tac tgc ctg acc ctg caa ggg ctg ggc	1521
Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu Gly	
435 440 445	
atc agc tgg ctg ggg ctg cgc tca ctg agg gaa ctg ggc agt gga ctg	1569
Ile Ser Trp Leu Gly Arg Ser Leu Arg Glu Leu Gly Ser Gly Leu	
450 455 460 465	
gcc ctc atc cac cat aac acc cac ctc tgc ttc gtg cac acg gtg ccc	1617
Ala Leu Ile His Asn Thr His Leu Cys Phe Val His Thr Val Pro	
470 475 480	
tgg gac cag ctc ttt cgg aac ccg cac caa gct ctg ctc cac act gcc	1665
Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr Ala	
485 490 495	
aac cgg cca gag gac gag tgt gtg ggc gag ggc ctg gcc tgc cac cag	1713
Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His Gln	
500 505 510	
ctg tgc gcc cga ggg cac tgc tgg ggt cca ggg ccc acc cag tgt gtc	1761
Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys Val	
515 520 525	
aac tgc agc cag ttc ctt cgg ggc cag gag tgc gtg gag gaa tgc cga	1809
Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys Arg	
530 535 540 545	
gta ctg cag ggg ctc ccc agg gag tat gtg aat gcc agg cac tgt ttg	1857
Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys Leu	
550 555 560	
ccg tgc cac cct gag tgt cag ccc cag aat ggc tca gtg acc tgt ttt	1905
Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys Phe	
565 570 575	
gga ccg gag gct gac cag tgt gtg gcc tgt gcc cac tat aag gac cct	1953
Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp Pro	
580 585 590	
ccc ttc tgc gtg gcc cgc tgc ccc agc ggt gtg aaa cct gac ctc tcc	2001
Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu Ser	
595 600 605	
tac atg ccc atc tgg aag ttt cca gat gag gag ggc gca tgc cag cct	2049
Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln Pro	
610 615 620 625	
tgc ccc atc aac tgc acc cac tcc tgt gtg gac ctg gat gac aag ggc	2097
Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys Gly	
630 635 640	
tgc ccc gcc gag cag aga gcc agc cct ctg acg tcc atc atc tct gcg	2145
Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Ile Ser Ala	
645 650 655	
gtg gtt ggc att ctg ctg gtc gtg gtc ttg ggg gtg gtc ttt ggg atc	2193
Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe Gly Ile	
660 665 670	

4 of 12

ctc atc aag cga cgg cag cag aag atc cgg aag tac acg atg cgg aga	2241
Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg Arg	
675 680 685	
ctg ctg cag gaa acg gag ctg gtg gag ccg ctg aca cct agc gga gcg	2289
Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly Ala	
690 695 700 705	
atg ccc aac cag gcg cag atg cgg atc ctg aaa gag acg gag ctg agg	2337
Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu Arg	
710 715 720	
aag gtg aag gtg ctt gga tct ggc gct ttt ggc aca gtc tac aag ggc	2385
Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys Gly	
725 730 735	
atc tgg atc cct gat ggg gag aat gtg aaa att cca gtg gcc atc aaa	2433
Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile Lys	
740 745 750	
gtg ttg agg gaa aac aca tcc ccc aaa gcc aac aaa gaa atc tta gac	2481
Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu Asp	
755 760 765	
gaa gca tac gtg atg gct ggt gtg ggc tcc cca tat gtc tcc cgc ctt	2529
Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg Leu	
770 775 780 785	
ctg ggc atc tgc ctg aca tcc acg gtg cag ctg gtg aca cag ctt atg	2577
Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu Met	
790 795 800	
ccc tat ggc tgc ctc tta gac cat gtc cgg gaa aac cgc gga cgc ctg	2625
Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg Leu	
805 810 815	
ggc tcc cag gac ctg ctg aac tgg tgt atg cag att gcc aag ggg atg	2673
Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly Met	
820 825 830	
agc tac ctg gag gat gtg cgg ctc gta cac agg gac ttg gcc gct cgg	2721
Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala Arg	
835 840 845	
aac gtg ctg gtc aag agt ccc aac cat gtc aaa att aca gac ttc ggg	2769
Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe Gly	
850 855 860 865	
ctg gct cgg ctg ctg gac att gac gag aca gag tac cat gca gat ggg	2817
Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp Gly	
870 875 880	
ggc aag gtg ccc atc aag tgg atg gcg ctg gag tcc att ctc cgc cgg	2865
Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg Arg	
885 890 895	
cgg ttc acc cac cag agt gat gtg tgg agt tat ggt gtg act gtg tgg	2913
Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val Trp	
900 905 910	
gag ctg atg act ttt ggg gcc aaa cct tac gat ggg atc cca gcc cgg	2961
Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala Arg	
915 920 925	
gag atc cct gac ctg ctg gaa aag ggg gag cgg ctg ccc cag ccc ccc	3009
Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro Pro	
930 935 940 945	

5 of 12

atc tgc acc att gat gtc tac atg atc atg gtc aaa tgt tgg atg att Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met Ile 950 955 960	3057
gac tct gaa tgt cgg cca aga ttc cgg gag ttg gtg tct gaa ttc tcc Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe Ser 965 970 975	3105
cgc atg gcc agg gac ccc cag cgc ttt gtg gtc atc cag aat gag gac Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu Asp 980 985 990	3153
ttg ggc cca gcc agt ccc ttg gac agc acc ttc tac cgc tca ctg ctg Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu Leu 995 1000 1005	3201
gag gac gat gac atg ggg gac ctg gtg gat gct gag gag tat ctg gta Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu Val 1010 1015 1020 1025	3249
ccc cag cag ggc ttc ttc tgt cca gac cct gcc ccg ggc gct ggg ggc Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Ala Gly Gly 1030 1035 1040	3297
atg gtc cac cac agg cac cgc agc tca tct acc agg agt ggc ggt ggg Met Val His His Arg His Arg Ser Ser Thr Arg Ser Gly Gly Gly 1045 1050 1055	3345
gac ctg aca cta ggg ctg gag ccc tct gaa gag gag gcc ccc agg tct Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Glu Ala Pro Arg Ser 1060 1065 1070	3393
cca ctg gca ccc tcc gaa ggg gct ggc tcc gat gta ttt gat ggt gac Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser Asp Val Phe Asp Gly Asp 1075 1080 1085	3441
ctg gga atg ggg gca gcc aag ggg ctg caa agc ctc ccc aca cat gac Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Thr His Asp 1090 1095 1100 1105	3489
ccc agc cct cta cag cgg tac agt gag gac ccc aca gta ccc ctg ccc Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu Pro 1110 1115 1120	3537
tct gag act gat ggc tac gtt gcc ccc ctg acc tgc agc ccc cag cct Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln Pro 1125 1130 1135	3585
gaa tat gtg aac cag cca gat gtt cgg ccc cag ccc cct tcg ccc cga Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro Arg 1140 1145 1150	3633
gag ggc cct ctg cct gct gcc cga cct gct ggt gcc act ctg gaa agg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu Arg 1155 1160 1165	3681
ccc aag act ctc tcc cca ggg aag aat ggg gtc gtc aaa gac gtt ttt Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val Phe 1170 1175 1180 1185	3729
gcc ttt ggg ggt gcc gtg gag aac ccc gag tac ttg aca ccc cag gga Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln Gly 1190 1195 1200	3777
gga gct gcc cct cag ccc cac cct cct cct gcc ttc agc cca gcc ttc Gly Ala Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala Phe 1205 1210 1215	3825

6 of 12

gac aac ctc tat tac tgg gac cag gac cca cca gag cgg ggg gct cca 3873
 Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala Pro
 1220 1225 1230
 ccc agc acc ttc aaa ggg aca cct acg gca gag aac cca gag tac ctg 3921
 Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr Leu
 1235 1240 1245
 ggt ctg gac gtg cca gtg tga accagaaggc caagtcccag aagccctgat 3972
 Gly Leu Asp Val Pro Val
 1250 1255
 gtgtcctcag ggagcagga aggccctgact tctgctggca tcaagagggtg ggagggccct 4032
 ccgaccactt ccaggggaac ctgccatgcc aggaacctgt cctaaggaac cttccttcct 4092
 gcttgagttc ccagatggct ggaaggggtc cagcctcggt ggaagaggaa cagcactggg 4152
 gagtctttgt ggattctgag gccctgcca atgagactct aggggtccagt ggatgccaca 4212
 gccagcttg gccctttcct tccagatcct gggtagtgaa agccttaggg aagctggcct 4272
 gagaggggaa ggggccctaa gggagtgtct aagaacaaaa gcgaccatt cagagactgt 4332
 ccctgaaacc tagtactgcc ccccatgagg aaggaacagc aatgggtgtca gtatccaggc 4392
 tttgtacaga gtgcttttct gtttagtttt tacttttttt gttttgtttt tttaaagatg 4452
 aaataaagac ccagggggag 4472

<210> 2
 <211> 1255
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
 1 5 10 15
 Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys
 20 25 30
 Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
 35 40 45
 Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
 50 55 60
 Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
 65 70 75 80
 Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu
 85 90 95
 Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
 100 105 110
 Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro
 115 120 125
 Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
 130 135 140
 Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
 145 150 155 160

7 of 12

Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
 165 170 175
 Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
 180 185 190
 His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser
 195 200 205
 Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys
 210 215 220
 Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys
 225 230 235 240
 Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
 245 250 255
 His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val
 260 265 270
 Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg
 275 280 285
 Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu
 290 295 300
 Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln
 305 310 315 320
 Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys
 325 330 335
 Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu
 340 345 350
 Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys
 355 360 365
 Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp
 370 375 380
 Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe
 385 390 395 400
 Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro
 405 410 415
 Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg
 420 425 430
 Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu
 435 440 445
 Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly
 450 455 460
 Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His Thr Val
 465 470 475 480
 Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr
 485 490 495
 Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His
 500 505 510
 Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys

8 of 12

515					520					525					
Val	Asn	Cys	Ser	Gln	Phe	Leu	Arg	Gly	Gln	Glu	Cys	Val	Glu	Glu	Cys
530						535					540				
Arg	Val	Leu	Gln	Gly	Leu	Pro	Arg	Glu	Tyr	Val	Asn	Ala	Arg	His	Cys
545					550					555					560
Leu	Pro	Cys	His	Pro	Glu	Cys	Gln	Pro	Gln	Asn	Gly	Ser	Val	Thr	Cys
				565					570					575	
Phe	Gly	Pro	Glu	Ala	Asp	Gln	Cys	Val	Ala	Cys	Ala	His	Tyr	Lys	Asp
			580					585					590		
Pro	Pro	Phe	Cys	Val	Ala	Arg	Cys	Pro	Ser	Gly	Val	Lys	Pro	Asp	Leu
		595					600					605			
Ser	Tyr	Met	Pro	Ile	Trp	Lys	Phe	Pro	Asp	Glu	Glu	Gly	Ala	Cys	Gln
	610					615					620				
Pro	Cys	Pro	Ile	Asn	Cys	Thr	His	Ser	Cys	Val	Asp	Leu	Asp	Asp	Lys
	625					630					635				640
Gly	Cys	Pro	Ala	Glu	Gln	Arg	Ala	Ser	Pro	Leu	Thr	Ser	Ile	Ile	Ser
				645					650					655	
Ala	Val	Val	Gly	Ile	Leu	Leu	Val	Val	Val	Leu	Gly	Val	Val	Phe	Gly
			660					665					670		
Ile	Leu	Ile	Lys	Arg	Arg	Gln	Gln	Lys	Ile	Arg	Lys	Tyr	Thr	Met	Arg
		675					680					685			
Arg	Leu	Leu	Gln	Glu	Thr	Glu	Leu	Val	Glu	Pro	Leu	Thr	Pro	Ser	Gly
	690					695					700				
Ala	Met	Pro	Asn	Gln	Ala	Gln	Met	Arg	Ile	Leu	Lys	Glu	Thr	Glu	Leu
	705					710					715				720
Arg	Lys	Val	Lys	Val	Leu	Gly	Ser	Gly	Ala	Phe	Gly	Thr	Val	Tyr	Lys
				725					730					735	
Gly	Ile	Trp	Ile	Pro	Asp	Gly	Glu	Asn	Val	Lys	Ile	Pro	Val	Ala	Ile
			740					745					750		
Lys	Val	Leu	Arg	Glu	Asn	Thr	Ser	Pro	Lys	Ala	Asn	Lys	Glu	Ile	Leu
		755					760					765			
Asp	Glu	Ala	Tyr	Val	Met	Ala	Gly	Val	Gly	Ser	Pro	Tyr	Val	Ser	Arg
	770					775					780				
Leu	Leu	Gly	Ile	Cys	Leu	Thr	Ser	Thr	Val	Gln	Leu	Val	Thr	Gln	Leu
	785					790					795				800
Met	Pro	Tyr	Gly	Cys	Leu	Leu	Asp	His	Val	Arg	Glu	Asn	Arg	Gly	Arg
				805					810					815	
Leu	Gly	Ser	Gln	Asp	Leu	Leu	Asn	Trp	Cys	Met	Gln	Ile	Ala	Lys	Gly
			820					825					830		
Met	Ser	Tyr	Leu	Glu	Asp	Val	Arg	Leu	Val	His	Arg	Asp	Leu	Ala	Ala
		835					840					845			
Arg	Asn	Val	Leu	Val	Lys	Ser	Pro	Asn	His	Val	Lys	Ile	Thr	Asp	Phe
	850					855					860				
Gly	Leu	Ala	Arg	Leu	Leu	Asp	Ile	Asp	Glu	Thr	Glu	Tyr	His	Ala	Asp
	865					870					875				880

9 of 12

Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg
 885 890 895
 Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val
 900 905 910
 Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala
 915 920 925
 Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro
 930 935 940
 Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met
 945 950 955 960
 Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe
 965 970 975
 Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu
 980 985 990
 Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu
 995 1000 1005
 Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu
 1010 1015 1020
 Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Ala Gly
 025 1030 1035 1040
 Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg Ser Gly Gly
 1045 1050 1055
 Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Glu Ala Pro Arg
 1060 1065 1070
 Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser Asp Val Phe Asp Gly
 1075 1080 1085
 Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Thr His
 1090 1095 1100
 Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu
 105 1110 1115 1120
 Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln
 1125 1130 1135
 Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro
 1140 1145 1150
 Arg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu
 1155 1160 1165
 Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val
 1170 1175 1180
 Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln
 185 1190 1195 1200
 Gly Gly Ala Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala
 1205 1210 1215
 Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala
 1220 1225 1230
 Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr

10 of 12

1235 1240 1245

Leu Gly Leu Asp Val Pro Val
1250 1255

<210> 3
<211> 18
<212> DNA
<213> Homo sapiens

<400> 3
tttccgatg aggagggc 18

<210> 4
<211> 27
<212> DNA
<213> Homo sapiens

<400> 4
cggaattcct gtcaccagct gcaccgt 27

<210> 5
<211> 69
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)..(69)

<400> 5
acc cac tcc tgt gtg gac ctg gat gac aag ggc tgc ccc gcc gag cag 48
Thr His Ser Cys Val Asp Leu Asp Asp Lys Gly Cys Pro Ala Glu Gln
1 5 10 15

aga gcc agc cct ctg acg tcc 69
Arg Ala Ser Pro Leu Thr Ser
20

<210> 6
<211> 23
<212> PRT
<213> Homo sapiens

<400> 6
Thr His Ser Cys Val Asp Leu Asp Asp Lys Gly Cys Pro Ala Glu Gln
1 5 10 15

Arg Ala Ser Pro Leu Thr Ser
20

<210> 7
<211> 21
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)..(21)

<400> 7
acc cac tcc cct ctg acg tcc 21

11 of 12

Thr His Ser Pro Leu Thr Ser
1 5

<210> 8
<211> 7
<212> PRT
<213> Homo sapiens

<400> 8
Thr His Ser Pro Leu Thr Ser
1 5

<210> 9
<211> 42
<212> PRT
<213> Homo sapiens

<400> 9
Cys Gln Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp
1 5 10 15

Asp Lys Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile
20 25 30

Ile Ser Ala Val Val Gly Ile Leu Leu Val
35 40

<210> 10
<211> 42
<212> PRT
<213> Homo sapiens

<400> 10
Cys Gln Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp
1 5 10 15

Asp Lys Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile
20 25 30

Ile Ser Ala Val Glu Gly Ile Leu Leu Val
35 40

<210> 11
<211> 30
<212> PRT
<213> Homo sapiens

<400> 11
Cys Gln Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Ala Ser Pro
1 5 10 15

Leu Thr Ser Ile Ile Ser Ala Val Val Gly Ile Leu Leu Val
20 25 30

<210> 12
<211> 26
<212> PRT
<213> Homo sapiens

<400> 12
Cys Gln Pro Cys Pro Ile Asn Cys Thr His Ser Pro Leu Thr Ser Ile
1 5 10 15

WO 00/20579

PCT/CA99/00912

12 of 12

Ile Ser Ala Val Val Gly Ile Leu Leu Val
20 25

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.

PCT/CA 99/00912

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/71 C12N15/85 C12N5/10 A61K38/17
A61K48/00 A61K39/395 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SIEGEL P M ET AL: "Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors." MOLECULAR AND CELLULAR BIOLOGY, vol. 14, no. 11, November 1994 (1994-11), pages 7068-7077, XP000867018	1-16, 18-21
Y	cited in the application figures 1,5 and 6 table 1 page 7073, right-hand column -page 7074, left-hand column — —/—	15,16, 18,19

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

24 February 2000

Date of mailing of the international search report

17/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 6818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

ALCONADA RODRIG..., A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 99/00912

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>KWONG, K. Y. ET AL: "Identification of a novel alternative splicing form of human HER2 / neu proto-oncogene."</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 205. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERICAN, XP000866525</p>	5,9-13, 15,16, 18-21
Y	abstract	15,16, 18,19
Y	<p>SHEPARD H M ET AL: "MONOCLONAL ANTIBODY THERAPY OF HUMAN CANCER: TAKING THE HER2 PROTOONCOGENE TO THE CLINIC"</p> <p>JOURNAL OF CLINICAL IMMUNOLOGY,US,PLENUM PUBLISHING CO, vol. 11, no. 3, 1 May 1991 (1991-05-01), page 117-127 XP000560916 ISSN: 0271-9142 page 119-125 figure 2; tables I-IV</p>	18,19
Y	<p>COLOMER R ET AL: "erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification"</p> <p>BRITISH JOURNAL OF CANCER, vol. 70, no. 5, November 1994 (1994-11), pages 819-825, XP000867330 figures 1-3 see results section</p>	15,16, 18,19
P,X	<p>KWONG K Y ET AL: "A novel splice variant of HER2 with increased transformation activity."</p> <p>MOLECULAR CARCINOGENESIS , vol. 23, no. 2, October 1998 (1998-10), pages 62-68, XP000867021 figures 1,2,4 table 1 page 64</p>	1-16, 18-21

-/-

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.

PCT/CA 99/00912

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>SIEGEL P M ET AL: "Elevated expression of activated forms of Neu / ErbB -2 and ErbB -3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer." EMBO JOURNAL, vol. 18, no. 8, 15 April 1999 (1999-04-15), pages 2149-2164, XP002131033 page 2154, right-hand column -page 2157, left-hand column figures 9-11 table IV</p>	<p>1-16, 18-21</p>

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 99/00912

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 12-16, 18 and 19, as far as concerning an in vivo method are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 17
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17

Present claim 17 relates to an extremely large number of possible methods. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found only for the methods involving the use of antibodies against the SPLICE erbB-2 protein or the use of erbB-2 antisense oligonucleotide. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over part of the claimed scope is impossible. Consequently, the search has not been carried out for that part of the claim that does not refer to the use of anti-SPLICE erbB-2 antibodies or antisense oligonucleotides complementary to the sequence of the polynucleotide encoding the SPLICE erbB-2.

The applicant's attention is drawn to the fact that claims, or part of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

(Remark: Present claims 3 and 4 refer, respectively, to a nucleic acid sequence encoding the SPLICE erbB-2 protein having the amino acid sequence according to SEQ ID NO:2 and to the nucleic acid sequence according to SEQ ID NO.1 encoding a SPLICE erbB-2 protein. However, the sequences provided in the description of the application (both in the computer-readable form and in figures 1 and 2) correspond to the wild-type human erbB-2 polynucleotide (SEQ ID NO.1) or polypeptide (SEQ ID NO:2). Therefore, the search for said claims was carried out considering the sequence of the alternate splice human erbB-2 provided in figure 3B.)